documents incorporated reference specified portions registrants definitive proxy statement filed commission pursuant regulation connection annual meeting incorporated reference part iii report based closing price per share excludes shares registrants common stock held executive officers directors stockholders whose ownership exceeds common stock outstanding june exclusion shares construed indicate person possesses power direct indirect direct cause direction management policies registrant person controlled common control registrant september registrant implemented twoforone stock split form stock dividend share per share amounts periods presented restated reflect stock split gilead sciences inc annual report table contents part item business item properties item legal proceedings item submission matters vote security holders part ii item market registrants common equity related stockholder matters item selected financial data item managements discussion analysis financial condition results operations item quantitative qualitative disclosures market risk item financial statements supplementary data item changes disagreements accountants accounting financial disclosure item controls procedures item b information part iiiitem directors executive officers registrant item executive compensation item security ownership certain beneficial owners management related stockholder matters item certain relationships related transactions item principal accountant fees services part iv item exhibits financial statement schedules signatures rights various trademarks copyrights trade names used business including following gilead gilead sciences hepsera viread vistide daunoxome ambisome emtriva truvada macugen registered trademark belonging eyetech pharmaceuticals inc sustiva registered trademark bristolmyers squibb company tamiflu registered trademark belonging hoffmannla roche report also includes trademarks service marks trade names companies part item business forwardlooking statements risk factors report includes forwardlooking statements particular statements expectations beliefs plans objectives assumptions future events performance contained incorporated reference report based forwardlooking statements current expectations future events believe expectations reasonable forwardlooking statements inherently subject risks uncertainties many beyond control actual results may differ materially suggested forwardlooking statements various reasons including discussed report heading risk factors affect gilead beginning given risks uncertainties cautioned place undue reliance forwardlooking statements forwardlooking statements included report made date hereof undertake specifically decline obligation update statements publicly announce results revisions forward looking statements reflect future events developments used report unless otherwise indicated us refers gilead subsidiaries overview gilead sciences inc biopharmaceutical company discovers develops commercializes therapeutics advance care patients suffering lifethreatening diseases multinational company eight approved products focus research clinical programs antiinfectives seeking add existing portfolio products internal discovery clinical development programs active product acquisition inlicensing strategy worldwide headquarters foster city california european headquarters paris france incorporated delaware june products viread oral formulation nucleotide analogue reverse transcriptase inhibitor dosed day part combination therapy treat human immunodeficiency virus hiv infection adults sell viread united states us commercial team wholesalers major european countries european commercial team distributors japan corporate partner japan tobacco exclusive worldwide license patent rights related technology viread institute organic chemistry biochemistry part academy sciences czech republic rega stichting vzw together iocbrega emtriva oral formulation nucleoside analogue reverse transcriptase inhibitor dosed day part combination therapy treat hiv infection adults sell emtriva united states us commercial team wholesalers major european countries european commercial team distributors exclusive worldwide license patent rights related technology emtriva emory university truvada oral tablet dosed day part combination therapy treat hiv infection adults fixeddose combination antihiv medications emtriva viread truvada combines mg emtricitabine emtriva mg tenofovir disoproxil fumarate viread truvada currently sold united states us commercial team wholesalers international commercial team began launching truvada european union following recent regulatory approval february exclusive worldwide license patent rights related technology components truvada iocbrega emory university ambisome proprietary liposomal formulation amphotericin b powerful antifungal agent treat serious invasive fungal infections caused various fungal species delivering amphotericin b proprietary liposomal formulation ambisome reduces rate severity kidney toxicity injectionrelated reactions associated amphotericin b allows patients receive higher doses amphotericin b ambisome approved sale countries including united states countries european union countries ambisome approved including united states authorized promote ambisome empirical treatment fungal infections treatment patients strong suspicion without definite confirmation exists potentially lifethreatening invasive fungal infection remaining countries ambisome approved use either firstline treatment serious invasive fungal infection secondline treatment conventional amphotericin b therapy fails conventional amphotericin b tolerated market ambisome major countries europe copromote ambisome united states fujisawa healthcare inc fujisawa hepsera oral formulation nucleotide analogue hepatitis b virus hbv dna polymerase inhibitor dosed day treat chronic hepatitis b hepsera approved sale united states treatment chronic hepatitis b adults evidence active viral replication either evidence persistent elevations serum aminotransferases alt ast histologically active liver disease us commercial team wholesalers sell hepsera united states sell hepsera major european union countries european commercial team distributors licensed rights commercialize hepsera solely treatment hepatitis b china japan korea taiwan rest asia latin america certainother territories glaxosmithkline gsk launched hepsera japan south korea taiwan exclusive worldwide license patent rights related technology adefovir dipivoxil iocbrega vistide antiviral medication treatment cytomegalovirus cmv retinitis patients aids cmv retinitis condition characterized lesions form patients retina affects persons weakened immune systems common patients aids vistide approved sale sold united states us commercial team gileads exus partner pfizer inc pfizer formerly pharmacia corporation countries treatment cmv retinitis patients aids daunoxome liposomal formulation anticancer agent daunorubicin approved sale sold countries treatment aidsrelated kaposis sarcoma sold united states us commercial team independent distributors abroad december decided discontinue selling product however subsequently received unanticipated requests europe reconsider selling daunoxome continuing sell product limited number countries currently evaluating supply sales strategy regard product royalty sources macugen antiangiogenic injection treatment neovascular agerelated macular degeneration amd drug inhibitor vascular endothelial growth factor vegf known play role development certain ophthalmic diseases macugen approved fda united states december began selling january product yet approved outside united states macugen developed eyetech pharmaceuticals inc eyetech using technology licensed us eyetech holds exclusive rights manufacture sell macugen worldwide subject eyetechs obligation pay us percentage net revenues eyetech generates macugen sales patents technology license eyetech expire united states europe tamiflu oral pill treatment prevention influenza b tamiflu class prescription drugs called neuraminidase inhibitors tamiflu approved countries including united states japan countries european union treatment influenza children adults tamiflu also approved united states european union prevention influenza adolescents adults developed tamiflu f hoffmannlaroche ltd roche roche exclusive right manufacture sell tamiflu worldwide subject obligation pay us percentage net revenues roche generates tamiflu sales subject reduction certain defined manufacturing costs following table lists aggregate product sales major products thousands product product product sales sales sales viread emtriva truvada total hiv products ambisome total product sales see note consolidated financial statements financial information geographic area products marketed products clinical trials research development seeking add existing portfolio products internal discovery clinical development programs active product acquisition inlicensing strategy acquisition triangle pharmaceuticals inc completed january research scientists foster city san dimas california durham north carolina engaged discovery development new molecules technologies hope lead new medicines novel formulations existing drugs therapeutic focus area life threatening infectious diseases research includes working proprietary nucleotide analogues develop treatments viral infections particularly hiv hepatitis c infection total research development rd expenses million compared million million research efforts area hepatitis c viral infection hcv include collaborations chiron corporation chiron genelabs technologies genelabs achillion pharmaceuticals inc achillion august entered agreement chiron research develop commercialize small molecule therapeutics certain hcv drug targets october entered research development agreement genelabs technologies genelabs discover develop commercialize nucleoside rna polymerase inhibitors treatment hcv infection november entered research development agreement achillion discover commercialize novel inhibitors hcv replication addition several inhouse programs designed discover small molecule inhibitors hcv rna polymerase hcv protease believe small molecule therapeutics treatment hcv infection could one day lead better treatment outcomes patients programs require extensive investments take many years see note consolidated financial statements discussion commercial operations us international commercial sales operations marketing subsidiaries australia canada france germany greece ireland italy new zealand portugal spain united kingdom commercial teams promote hiv hbv products viread emtriva truvada hepsera direct field contact physicians hospitals clinicsand healthcare providers involved treatment patients hiv hiv products chronic hepatitis b hepsera teams also promote ambisome infectious disease specialists hematologists intensive care units hospitals home health care providers cancer specialists countries outside united states agreements thirdparty distributors including distributors certain countries marketing operations promote sell distribute products international distribution agreements generally provide distributor exclusive right sell one products particular country several countries specified period time december announced program pursuant sell viread cost countries africa fifteen countries designated least developed united nations expanded program august include truvada taking steps ensure viread truvada products sold program used serve patients developing world diverted markets see international distribution collaborative relationships part business strategy establish collaborations companies assist clinical development andor commercialization certain products product candidates provide support research programs also evaluate opportunities acquiring products rights products technologies complementary business companies description accounting relationships found note consolidated financial statements included report following list representative collaborative relationships collaborator program area year signing bristolmyers squibb hiv achillion hcv genelabs hcv japan tobacco hiv glaxosmithkline hepsera archemix selex technology eyetech macugen roche tamiflu pfizer vistide fujisawa ambisome bristolmyers squibb company december entered collaboration agreement bristolmyers squibb company bms develop commercialize fixeddose combination gileads truvada bmss sustiva efavirenz united states structured joint venture gilead bms formed limited liability company bristolmyers squibb gilead sciences llc approved new product would first complete highly active antiretroviral therapy haart treatment regimen hiv available fixeddose combination taken daily fixeddose combinations contain multiple medicines formulated together may help simplify hiv therapy patients providers joint venture companies work partnership complete development us regulatory filings fixeddose regimen subject receiving marketing approval fixeddose regimen companies share responsibility commercializing product united states companies provide funding fieldbased sales representatives support promotional efforts combination product terms collaboration gilead bms grant royaltyfree sublicenses joint venture use respective companyowned technologies return granted license use jointly created intellectual property gileads bms ownership interests joint venture reflect respective economic interests based fraction net selling price fixeddose combination product attributable truvada sustiva respectively adjusted annual basis since net selling price truvada may change time relative net selling price sustiva joint venturers respective economic interests joint venture may vary annually academic consulting relationships supplement research development efforts part regular business enter arrangements universities medical research institutions arrangements often provide us rights patents patent applications technology owned institutions return payments fees relating use rights emory university university georgia research foundation inc emtricitabine april triangle obtained january acquired part acquisition triangle exclusive worldwide license emory universitys rights purified forms emtricitabine use hiv hbv fields obligated make certain milestone royalty payments emory including annual minimum royalties beginning third year first fda registration granted antihiv product incorporating emtricitabine technology united states third year first registration granted antihbv product incorporating emtricitabine technology certain major market countries hiv hbv indications respectively triangle began paying license maintenance fees development milestones yet achieved may emory gsk settled litigation pending united states district court relating emtricitabine became exclusive licensee us foreign patents patent applications filed burroughs wellcome co use emtricitabine treat hepatitis b settlement agreements obligated pay royalties gsk net sales products containing emtricitabine addition emory also received access development clinical data drug substance held gsk relating emtricitabine may emory gsk shire pharmaceuticals group plc shire settled worldwide patent disputes involving lamivudine emtricitabine terms settlement emory received exclusive license shire shires patents relating emtricitabine methods use manufacture shire gsk received exclusive licenses emorys patents relating lamivudine terms license agreement emory automatically acquired exclusive sublicense shire patents relating emtricitabine granted terms settlement thereby resolving previously pending patent disputes regarding emtricitabine md anderson cancer centerin entered agreement md anderson cancer center relating hepsera agreement currently pay md anderson cancer center percentage net revenues based upon sales hepsera agreement md anderson cancer center terminates later patent expiration ten years first commercial sale iocbrega entered agreements iocbrega relating viread hepsera vistide subsequently amended agreements include truvada agreements received iocbrega exclusive right manufacture use sell nucleotide compounds covered agreements agreements pay percentage net revenues based upon sales viread truvada hepsera vistide iocbrega agreements iocbrega terminate individual country basis later patent expiration ten years first commercial sale addition iocbrega may terminate licenses particular product key market absence commercial sales product within months regulatory approval university license equity holdings inc ongoing collaborative arrangement university license equity holdings inc ulehi successor university technology corporation predecessor university research corporation technology holding company university colorado boulder relating selex technology identify aptamers arrangement ulehi granted us present future rights inventions covered patents patent applications selex technology improvements selex technology makes discovers oligonucleotides molecules makes using selex technology computer software related selex technology required pay ulehi certain variable royalties based revenues generated sales products derived using selex technology including revenues based license agreement eyetech relating macugen developing world collaborations bill melinda gates foundation family health international october entered agreement bill melinda gates foundation family health international fhi provide viread fhis multinational clinical trial evaluating vireads effectiveness method reducing risk hiv infection among sexually active adults regularly exposed hiv clinical trials conducted fhi funded million threeyear grant gates foundation dart study november entered collaborative agreement medical research council mrc united kingdom boehringer ingelheim gmbh gsk connection fiveyear clinical study conducted mrc antiretroviral hiv therapy africa trial called dart trial development antiretroviral therapy africa aimed studying clinical versus laboratory monitoring practices structured treatment interruptions versus continuous antiretroviral therapy adults hiv infection subsaharan africa agreed provide viread cost dart study institute one world health january entered agreement institute one world health pursuant provide ambisome cost phase clinical trial evaluating ambisome treatment visceral leishmaniasis paromomycin india greatest global burden visceral leishmaniasis clinical trial conducted institute one world health partnership world health organization international distribution various agreements distributors europe asia latin america middle east africa grant distributors exclusive right sell viread emtriva hepsera ambisome daunoxome particular country countries specified period time agreements also provide collaborative efforts us distributor obtaining regulatory approval product particular country marketing product country agreements establish price distributor must pay product require us deliver quantities product ordered distributor manufacturing ambisome manufacture ambisome commercial quantities two separate adjacent facilities san dimas california medicines control agency united kingdom fda approved commercial production ambisome facilities produced import ambisome european union manufacturing facility dublin ireland perform quality control testing final labeling packaging distribution european union elsewhere use commercially available materials equipment manufacture products currently obtain amphotericin b cholesterol use manufacture ambisome single approved suppliers ambisome sold freezedried product currently freezedry ambisome san dimas manufacturing facility also use third party freezedry additional product needed given current projections ambisome demand believe sufficient capacity meet future demand also option installing additional freezedrying capacity san dimas additional supply become necessary unable install additional freeze drying capacity san dimas locate appropriate third parties meet need ability meet increased ambisome demand would diminished macugen manufacture macugen commercial quantities fda approved facilities san dimas california manufacturing agreement eyetech use commercially available materials equipment manufacture product currently eyetech provides raw materials used manufacture macugen including pegaptanib sodium active ingredient macugen single approved suppliers contracted eyetech part manufacturing process currently produce fill macugen san dimas manufacturing facility given eyetechs current projections macugen demand believe sufficient capacity meet future demand also option installing additional production filling capacity san dimas additional supply become necessary unable install additional production filling capacity san dimas locate appropriate third parties meet need ability meet increased macugen demand would diminished macugen sold liquid form filled syringes san dimas facilities syringes supplied single approved supplier contracted eyetech antiviral products contract third parties manufacture antiviral drugs clinical commercial purposes including viread emtriva truvada hepsera vistide manufacture tenofovir disoproxil fumarate bulk drug substance two contract manufacturers viread tablets manufactured two contract manufacturers manufacture emtricitabine bulk drug substance two contract manufacturers emtriva tablets manufactured one contract manufacturer us second contract manufacturer currently qualified manufacture truvada tablets single contract manufacturer united states second contract manufacturer currently qualified obtained qualification united states european union two contract manufacturers adefovir dipivoxil bulk drug substance two contract manufacturers hepsera tablet commercial supply europe two contract manufacturers one also qualified commercial supply united states second currently qualified two suppliers approved fda european union manufacture cidofovir bulk drug substance used vistide single fda emea approved supplier vistide drug product roche responsible manufacturing tamiflu january roche announced due production problems liquid suspension form tamiflu approved treatment children young one yearold available however liquid suspension form tamiflu returned market time flu season production issues affect availability tablet form tamiflu adults adolescents years older japan flu season particularly severe roches sublicensee chugai corporation unable meet heightened demand satisfactorily january chugai issued press release attributing failure part manufacturing problems november chugai announced recall tamiflu resulting reduced net sales royalties roche however royalty income tamiflu net sales increased substantially due primarily severe flu season united states late commercialscale manufacturing facilities antiviral products future antiviral products need develop additional manufacturing capabilities establish additional third party suppliers manufacture sufficient quantities product candidates undertake clinical trials manufacture sufficient quantities products approved commercial sale unable develop manufacturing capabilities internally contract large scale manufacturing third parties acceptable terms future antiviral products ability conduct largescale clinical trials meet customer demand commercial products would adversely affected believe technology use manufacture products compounds proprietary antiviral products disclosed necessary aspects technology contract manufacturers enable manufacture products compounds us agreements manufacturers intended restrict using revealing technology certain manufacturers comply restrictions addition manufacturers could develop technology related work perform us may need manufacture products compounds could required enter agreement manufacturer wanted use technology allow another manufacturer use technology manufacturer could refuse allow us use technology could demand terms use technology acceptable believe compliance material environmental regulations related manufacture products patents proprietary rights patents proprietary rights important business properly designed enforceable patent difficult competitors use technology create competitive products difficult competitors obtain patent prevents us using technology create part business strategy actively seek patent protection united states internationally file additional patent applications appropriate cover improvements compounds products technology also rely trade secrets internal knowhow technological innovations agreements third parties develop maintain protect competitive position ability competitive depend success strategy number patents patent applications rights patents related compounds products technology certain issued patents enforceable provide adequate protection pending patent applications result issued patents following table shows actual estimated expiration dates united states europe primary patents patents may issue pending applications cover compounds marketed products product candidates products us patent expiration european patent expiration vistide hepsera ambisome tamiflu viread emtriva truvada patents covering viread hepsera vistide emtriva truvada held third parties acquired exclusive rights patents agreements parties see collaborative relationships academic consulting relationships patents cover active ingredients ambisome instead hold patents liposomal formulations compound also protect formulations trade secrets patent filings covering forms hepsera china certain asian countries although applications pending various asian countries including china relate specific forms formulations hepsera asia major market hbv therapies may obtain patents compounds many years obtain marketing approval patents limited life may begin run prior commercial sale related product commercial value patent may limited however may able apply patent term extensions example extensions patents vistide granted united states number european countries compensating part delays obtaining marketing approval similar patent term extensions may available products developing certain obtain themit also important infringe patents proprietary rights others violate agreements grant proprietary rights us infringe patents violate agreements could prevented developing selling products using processes covered patents agreements could required obtain license third party allowing us use technology certain required could obtain license thirdparty technology could obtain one reasonable cost able obtain required license could adversely affected patent applications confidential least period time including sometimes united states patent issues may pending patent applications patents eventually issue prevent us developing selling certain products unless obtain license use patented technology patents relating pharmaceutical biopharmaceutical biotechnology products compounds processes cover existing compounds products processes likely file future always provide complete adequate protection future litigation reexamination proceedings regarding enforcement validity existing patents future patents could invalidate patents substantially reduce protection addition pending patent applications patent applications filed collaborative partners may result issuance patents may result patents provide adequate protection result may able prevent third parties developing compounds products developed developing addition certain countries permit enforcement patents manufacturers able sell generic versions products countries also rely unpatented trade secrets improvements unpatented internal knowhow technological innovation particular great deal liposomal manufacturing expertise key component liposomal technology covered patents instead protected trade secret protect rights mainly confidentiality agreements corporate partners employees consultants vendors agreements provide confidential information developed made known individual course relationship us kept confidential used disclosed third parties except specified circumstances case employees agreements provide inventions made individual employed us exclusive property certain parties comply confidentiality agreements adequate remedies breach trade secrets otherwise become known independently discovered competitors research development agreements inventions discovered certain cases become jointly owned us corporate partner cases become exclusive property one us difficult determine owns particular invention disputes could arise regarding inventions competition products development programs target number diseases conditions including viral fungal infections many commercially available products diseases large number companies institutions spending considerable amounts money resources develop additional products treat diseases current products compete available products based primarily efficacy safety tolerability acceptance doctors patient compliance patent protection ease use price insurance reimbursement coverage distribution marketing adaptability various modes dosing products market future also compete products offered competitors competitors introduce data show improved characteristics products improve increase marketing efforts simply lower price products sales products could decrease also certain products may develop future compare favorably products offered competitors existing future products compare favorably new products developed competitors ability competitive also depends upon ability attract retain qualified personnel obtain patent protection otherwise develop proprietary products processes secure sufficient capital resources substantial period takes develop product hiv products hiv competitive landscape becoming crowded complicated treatment trends continue evolve growing number antihiv drugs currently sold advanced stages clinical development twentysix branded drugs available united states zerit stavudine dt sold bristolmyers squibb bms fixed combination products combivir azt tc trizivir azt tc abc sold gsk represent direct competition hiv products companies process launching formulations existing drugs indicated fda daily oral dosing including gsks mg dose epivir lamivudine tc recently approved antiretroviral products include epzicom fixed dose combination ziagen epivir gsk approved united states european union fuzeon injectable integrase inhibitor rochetrimeris reyataz atazanivir sulfate onceaday protease inhibitor bms tipranavir nonpeptidic protease inhibitor boehringeringelheim gsk filed application approval oncedaily dose ziagen abacavir sulfate companies competing hiv therapeutic category pfizer merck abbott bmss videx ec didanosine became first generic hiv product united states gsks retrovir azt expected face generic competition early united states effect overall us market hiv products unknown price decreases hiv products may result ambisome ambisome faces strong competition several current expected competitors current competitors include conventional amphotericin b made bms numerous generic manufacturers caspofungin product developed merck marketed cancidas united states caspofungin elsewhere voriconazole developed pfizer marketed vfend lipidbased amphotericin b products approved sale united states throughout europe including abelcet sold enzon corp united states canada japan medeus pharma ltd europe amphotec sold intermune pharmaceuticals inc presently unapproved expected competitors include class treatments called echinocandins including fujisawas micafungin received marketing approval japan october review regulatory approval united states canada anidulafungin vicuron inc formerly versicor inc product candidate evaluated multiple latestage clinical trials finally schering plough developing noxafil posaconazole currently phase trials competition current expected competitors eroded likely continue erode revenues receive sales ambisome hepsera hepsera faces significant competition existing expected therapies treating patients infected hbv significantly entecavir oral nucleoside analogue developed bms expected launched late daily oral antiviral bms filed approval us fda prescription drug user fee act pdufa action date april epivirhbv lamivudine developed gsk collaboration shire pharmaceuticals sold major countries throughout north south america europe asia orally administered nucleoside analogue inhibits hbv dna polymerase introna interferon alfab sold schering plough major countries throughout north south america europe asia introna injectable drug immunomodulatory effects hepsera may also face competition clinicalstage candidates including idenixs ldt oral nucleoside analogue currently phase trials well roches pegasys pegylated interferon alfaa expected approved chronic hepatitis b united states late tamiflu tamiflu competes relenza antiflu drug sold gsk relenza neuraminidase inhibitor delivered orallyinhaled dry powder generic competitors include amantadine oral tablet inhibits replication influenza virus rimantadine also oral antiviral vistide vistide competes number drugs also treat cmv retinitis including ganciclovir sold intravenous oral formulations roche ocular implant bausch lomb incorporated valganciclovir also marketed roche foscarnet intravenous drug sold astrazeneca formivirsen drug injected directly eye sold cibavision number companies pursuing development technologies competitive research programs competing companies include specialized pharmaceutical firms large pharmaceutical companies acting either independently together biopharmaceutical companies furthermore academic institutions government agencies public private organizations conducting research may seek patent protection may establish collaborative arrangements competitive products programs anticipate face increased competition future competitors introduce new products market new technologies become available determine existing products new products competitors develop effective effectively marketed sold develop competitive products could render technology products obsolete noncompetitive recover money resources used develop products government regulation operations activities subject extensive regulation numerous government authorities united states countries united states drugs subject rigorous fda regulation federal food drug cosmetic act federal state statutes regulations govern testing manufacture safety effectiveness labeling storage record keeping approval advertising promotion products result regulations product development product approval process expensive time consuming fda must approve drug sold united states general process approval follows preclinical testing test drug candidate humans must study drug laboratory experiments animals generate data support drugs potential safety benefits submit data fda investigational new drug application ind seeking approval test compound humans clinical trials fda accepts investigational new drug application study drug human clinical trials determine drug safe effective clinical trials involve three separate phases often overlap take many years expensive three phases subject considerable regulation follows phase drug given small number healthy human subjects patients test safety dose tolerance pharmacokinetics metabolism distribution excretion phase drug given limited patient population determine effect drug treating disease best dose drug possible side effects safety risks drug phase compound appears effective safe phase clinical trials phase clinical trials commenced confirm results phase clinical trials longterm involve significantly larger population conducted numerous sites different geographic regions carefully designed provide reliable conclusive data regarding safety benefits drug uncommon drug appears promising phase clinical trials fail rigorous reliable phase clinical trials fda approval process believe data phase clinical trials show adequate level safety effectiveness file new drug application nda thefda seeking approval sell drug particular use fda review nda often hold public hearing independent advisory committee expert advisors asks additional questions regarding drug committee makes recommendation fda binding fda generally followed fda fda agrees compound met required level safety effectiveness particular use allow us sell drug united states use unusual however fda reject application believes drug safe enough effective enough believe data submitted reliable conclusive point process development drug could stopped number reasons including safety concerns lack treatment benefit certain clinical trials currently conducting conduct future completed successfully within specified time period may choose fda may require us delay suspend clinical trials time appears patients exposed unacceptable health risk drug candidate appear sufficient treatment benefit fda may also require us complete additional testing provide additional data information improve manufacturing processes procedures facilities may require extensive postmarketing testing surveillance monitor safety benefits product candidates determines new drug application contain adequate evidence safety benefits drug addition even fda approves drug could limit uses drug fda withdraw approvals believe complying regulatory standards problems uncovered occur approval addition obtaining fda approval drug obtain fda approval manufacturing facilities drug sell including companies manufacture drugs us well facilities subject periodic inspections fda fda must also approve foreign establishments manufacture products sold united states facilities subject periodic regulatory inspection manufacturing facilities located california including san dimas facility foster city facility also must licensed state california compliance local regulatory requirements drugs treat serious lifethreatening diseases conditions adequately addressed existing drugs may designated fast track products fda may eligible accelerated sixmonth review accelerated approval case viread truvada drugs receiving accelerated approval must monitored postmarketing clinical trials order confirm safety benefits drug also subject federal state local regulations regarding workplace safety protection environment use hazardous materials chemicals viruses various radioactive compounds research development activities eliminate risk accidental contamination injury materials misuse accidents involving materials could lead significant litigation fines penalties drugs also subject extensive regulation outside united states european union centralized approval procedure authorizes marketing product countries european union includes major countries europe procedure used decentralized system approval one country european union used obtain approval another country european union simplified application process approval centralized procedure pricing reimbursement approvals also required countries vistide viread hepsera emtriva february truvada approved european union centralized procedure viread hiv drug reviewed accelerated approval european union hepsera received traditional review emtriva march applied marketing applications truvada treatment hiv european union began european launch truvada following regulatory approval received february pricing reimbursement insurance companies health maintenance organizations hmos thirdparty payors federal state governments seek limit amount charge drugs example certain foreign markets pricing negotiations often required obtain approval product united states expect continue number federal state proposals implement drug price control addition managed care organizations becoming common united states continue seek lower drug prices announcement proposals efforts cause stock price decrease proposals adopted revenues could decrease ability sell drugs also depends availability reimbursement governments private insurance companies governments insurance companies often demand rebates predetermined discounts list prices expect products developing particularly hivaids indications subject reimbursement issues certain products obtain regulatory approval reimbursed governments insurance companies regulatory approval prices required foreign countries certain countries condition approval product agreement seller sell product certain price country past required price reductions connection product approval certain foreign countries also require price approved product reduced product marketed period time certain regulatory authorities future establish lower prices regulatory action reducing price products one country practical effect requiring us reduce prices countries european governments notably germany italy implemented considering legislation would require pharmaceutical companies sell products subject reimbursement mandatory discount mandatory discounts would reduce revenue receive drug sales certain developing countries significantly affected hiv aids parallel importing generic competition may occur adversely affect revenues sales market share viread addition governments could take regulatory action disallow pricing combination products truvada sum prices component drugs marketed particular country employees february approximately fulltime employees believe good relations employees website website address wwwgileadcom make available free charge website annual report quarterly reports form q current reports form k directors officers section reports required sec filings amendments reports soon reasonably practicable filing providing hyperlink edgar website containing reports risk factors affect gilead evaluating business carefully consider following risks addition information report following risks couldmaterially adversely affect business operating results financial condition substantially revenues derived sales limited number products unable maintain continue growing sales hiv products maintain sales ambisome results operations may adversely affected currently dependent sales hiv products especially viread ambisome support existing operations although viread comprised hiv product sales important consider viread emtriva truvada collectively future sales three products intimately tied one another together sales hiv products ambisome accounted approximately total product revenues year ended december unable continue growing hiv product revenues maintain ambisome sales results operations likely suffer may need scale back operations hiv product sales year ended december million total revenues ambisome product sales royalties year ended december million total revenues may able continue growth rate sales hiv products current sales level ambisome reasons stated risk factor section particular following reasons face significant competition businesses substantially greater resources merck pfizer released new products compete ambisome glaxosmithkline markets fixeddose combination products compete truvada competitors products operated fields compete longer ambisome sales volumes relatively flat compared hiv products ambisome used longer period time many patients combination products additional studies conducted new issues respect safety resistance interactions drugs may arise could cause us provide additional warnings labels narrow approved indications halt sales product could reduce revenues product matures private insurers government reimbursers often reduce amount reimburse patients products increases pressure us reduce prices large part market hiv products patients already taking hiv drugs successful encouraging physicians change patients prescriptions hiv products sales hiv products limited generic hiv products introduced major markets ability maintain pricing may affected fail commercialize new products expand indications existing products prospects future revenues stock price may adversely affected introduce new products increase revenues existing products able grow revenues fail increase sales hiv products may able increase revenues expand research development efforts may successful efforts collaboration bristol myers squibb company formulate onceaday one pill combination truvada sustiva failure achieve objectives expected may material adverse effect business results operations significant safety issues arise marketed products sales may decline would adversely affect results operations data support marketing approvals products form basis safety warnings product labels obtained controlled clinical trials limited duration cases limited postapproval use components truvada emtriva viread studied individually safety efficacy studies truvada still ongoing following approval products used longer periods time many patients taking numerous medicines many underlying health problems would monitored dosing compliance drugs used longer periods time patients found expect continue find new issues safety resistance drug interaction issues may require us provide additional warnings labels narrow approved indications could reduce market acceptance products serious safety resistance interaction issues arise marketed products sales products could limited halted us regulatory authorities operations depend compliance complex fda comparable international regulations failure obtain broad approvals timely basis achieve continued compliance could delay halt commercialization products products develop must approved marketing sale regulatory authorities approved subject extensive regulation fda comparable regulatory agencies countries continuing clinical trials ambisome viread hepsera emtriva truvada currently approved additional uses anticipate file marketing approval additional countries additional products next several years products may fail receive marketing approval timely basis addition marketed products manufacture sell products subject extensive continued regulation review discovery previously unknown problems marketed products problems manufacturing promotional activities may result restrictions products including withdrawal products market fail comply applicable regulatory requirements could subject penalties including fines suspensions regulatory approvals product recalls seizure products criminal prosecution recently formation independent drug safety office announced tasked monitoring safety approved products new office may increase difficulty length time required new drugs obtain marketing approval office may create postapproval obligations would required comply results clinical trials uncertain may support continued development product pipeline would adversely affect prospects future revenue growth required demonstrate safety effectiveness products develop intended use extensive preclinical studies clinical trials results preclinical early clinical studies always accurately predict results later largescale clinical trials even successfully completed largescale clinical trials may result marketable products products development fail achieve primary endpoint clinical trials safety issues arise commercialization drug candidate could delayed halted addition clinical trials involving commercial products could raise new safety issues existing products reduce revenues manufacturing problems could delay product shipments regulatory approvals may adversely affect results operations depend third parties perform manufacturing activities effectively timely basis third parties fail perform required could impair ability deliver products timely basis cause delays clinical trials applications regulatory approval events could harmour competitive position manufacturing process pharmaceutical products highly regulated regulators may shut manufacturing facilities believe comply regulations manufacturers subject fdas current good manufacturing practices extensive regulations governing manufacturing processes stability testing recordkeeping quality standards similar regulations effect countries addition manufacturing operations subject routine inspections regulatory agencies viread hepsera vistide emtriva truvada rely third parties manufacture bulk drug substance final drug product clinical commercial purposes addition roche responsible manufacturing tamiflu thirdparty manufacturers may develop problems control problems may adversely affect business example january roche announced due production problems liquid suspension form tamiflu approved treatment children young one year old available japan flu season particularly severe roches sublicensee chugai corporation unable meet heightened demand satisfactorily january chugai issued press release attributing failure part manufacturing problems problems japan reduced net sales tamiflu royalty roche manufacture ambisome facilities san dimas california formulation manufacturing facilities united states manufacturing facility ireland conducts quality control testing labeling packaging addition use third parties alternate contract suppliers fill freeze dry certain batches product event natural disaster including earthquake equipment failure strike difficulty may unable replace manufacturing capacity timely manner would unable manufacture ambisome meet market needs may able obtain materials necessary manufacture products could limit ability generate revenues many materials utilize operations made one facility example depend single suppliers high quality amphotericin b distearoylphosphatidylcholine high quality cholesterol used manufacture one liposomal products suppliers key components materials must named new drug application filed fda product significant delays occur qualification new supplier required delivery material suppliers interrupted reason may unable ship viread ambisome hepsera emtriva truvada vistide supply products development clinical trials depend relationships companies sales marketing performance revenues failure maintain relationships would negatively impact business rely number significant collaborative relationships major pharmaceutical companies sales marketing performance include collaborations fujisawa sumitomo ambisome gsk hepsera roche tamiflu pfizer vistide japan tobacco viread emtriva truvada recently announced joint venture bristolmyers squibb develop commercialize fixeddose combination truvada sustiva certain countries rely international distributors sales ambisome viread emtriva european countries intend rely international distributors sales hepsera relationships also involve clinical development products partners reliance collaborative relationships poses number risks including able control whether corporate partners devote sufficient resources programs products disputes may arise future respect ownership rights technology developed corporate partners disagreements corporate partners could lead delays termination research development commercialization product candidates result litigation arbitration contracts corporate partners may fail provide significant protection may fail effectively enforced one partners fails perform corporate partners considerable discretion electing whether pursue development additional products may pursue alternative technologies products either collaboration competitors corporate partners marketing rights may choose devote fewer resources marketing products products development distributors corporate partners may unable pay us given risks great deal uncertainty regarding success current future collaborative efforts efforts fail product development commercialization new products could delayed revenue existing products could decline april licensing agreement gsk gave gsk right control clinical regulatory development commercialization hepsera territories asia africa latin america include major markets hepsera china japan taiwan korea success hepsera territories depend almost entirely efforts gsk regard gsk promotes epivirhbv product competes hepsera consequently gsks marketing strategy hepsera may influenced promotion epivirhbv receive royalties gsk equal percentage gsks net sales hepsera well net sales gsks epivirhbv gsk fails devote sufficient resources succeed developing commercializing hepsera territories potential revenues sales hepsera may substantially reduced expenses associated clinical trials sales fluctuations result inventory levels held wholesalers may cause earnings fluctuate could adversely affect stock price clinical trials required regulatory approval products well clinical trials required conduct approval extremely expensive difficult accurately predict control amount timing expenses uneven unexpected spending programs may cause operating results fluctuate quarter quarter addition approximately product sales united states three distributors amerisourcebergen corp cardinal health inc mckesson corp inventory levels held wholesalers may fluctuate significantly could cause sales result operating results fluctuate unexpectedly quarter quarter example based review ndc health corp prescription trends ims health inc inventory data actual viread sales believe quarter ended june wholesalers built inventory levels estimated months believe inventory buildup followed equivalent possibly greater inventory reduction quarter ended september know inventory management agreements entered year three major us wholesalers continue effective matching inventory levels end user demand rely wholesalers estimate end user demand approximately half product sales occur outside united states currency fluctuations may cause earnings fluctuate could adversely affect stock pricea significant percentage product sales denominated foreign currencies increases value us dollar foreign currencies past reduced future may reduce us dollar equivalent sales negatively impact financial condition results operations use foreign currency forward contracts hedge percentage forecasted international sales primarily denominated euro currency also hedge portion accounts receivable balances denominated foreign currencies reduces eliminate exposure currency fluctuations date sale recorded date cash collected additionally mitigate impact currency rate fluctuations cash outflows certain foreign currencydenominated raw materials purchases enter foreign exchange forward contracts hedge foreign currencydenominated accounts payable although use forward contracts reduce impact foreign currency fluctuations future results efforts may successful fluctuations could adversely affect results operations face credit risks european customers may adversely affect results operations particularly subject credit risk european customers european product sales government owned supported customers greece italy portugal spain subject significant payment delays due government funding reimbursement practices accounts receivable government owned supported customers countries totaled million december significant changes occur reimbursement practices european governments government funding becomes unavailable may able collect amounts due us customers results operations would adversely affected plan supply viread truvada cost certain developing countries may expose us liability would material adverse affect results operations financial condition launched distribution program pursuant supply viread truvada cost countries africa fifteen countries designated least developed united nations supply distribution drugs resourcepoor environment complicated undertaking program develops could face unforeseen challenges risks could give rise unforeseen liabilities example patients less developed countries using viread truvada may closely supervised doctor would developed nations accordingly may increased likelihood viread truvadarelated complications going undetected untreated could result significant liability gilead product revenues could reduced imports countries products available lower prices prices products based local market economics competition sometimes differ country country sales countries relatively higher prices may reduced products imported countries lower price markets cases pharmaceutical products sold steeply discounted prices developing world reexported european countries could resold much higher prices happens products particularly viread truvada agreed provide cost countries africa fifteen countries designated least developed countries united nations revenues would adversely affected addition european union required permit cross border sales allows buyers countries governmentapproved prices products relatively high purchase products legally countries must sold lower prices additionally us consumers able purchase products including hiv medicines internet pharmacies countries substantial discounts crossborder sales could adversely affect revenues countries may required grant compulsory licenses hiv products face generic competition hiv products number developing countries government officials groups suggested pharmaceutical companies make drugs hiv infection available low cost alternatively governments countries could require grant compulsory licenses allow competitors manufacture sell versions products thereby reducing sales certain countries permit enforcement patents manufacturers able sell generic versions products countries compulsory licenses sales generic versions products could significantly reduce sales adversely affect results operations existing products subject reimbursement government agencies third parties pharmaceutical pricing reimbursement pressures may reduce profitability successful commercialization products depends part availability governmental third party payor reimbursement cost products related treatments government health administration authorities private health insurers organizations generally provide reimbursement government authorities thirdparty payors increasingly challenging price medical products services particularly innovative new products therapies resulted lower average sales prices example majority sales ambisome vistide significant percentage sales viread hepsera subject reimbursement government agencies resulting significant discounts list price rebate obligations business may adversely affected increase us international pricing pressures pressures arise rules practices managed care groups judicial decisions governmental laws regulations related medicare medicaid health care reform pharmaceutical reimbursement policies pricing general europe success hepsera tamiflu emtriva viread truvada also depend largely obtaining maintaining government reimbursement many european countries including united kingdom france patients use prescription drugs reimbursed governments addition negotiating prices governmental authorities delay commercialization twelve months also expect success products development particularly europe depend ability obtain reimbursement even reimbursement available reimbursement policies may adversely affect ability sell products profitable basis example europe many international markets governments control prices prescription pharmaceuticals expect prices prescription pharmaceuticals decline life product volumes increase well previous years seen significant price decreases products across much europe believe continue foreseeable future governments struggle escalating health care spending result pricing practices may become difficult maintain historic levels profitability achieve expected rates growth results operations could adversely affected future health care reforms united states recent years new legislation proposed federal state levels would effect major changes health care system either nationally state level proposals included prescription drug benefit proposals medicare beneficiaries recently passed congress additionally states enacted health care reform legislation federal state developments possible impact proposed legislation reforms unclear may result pricing reimbursement restrictions could adversely impact revenueswe may able obtain effective patents protect technologies use competitors patents companies could require us stop using pay use required technology success depend significant degree ability obtain patents licenses patent rights preserve trade secrets operate without infringing proprietary rights others number us foreign patents patent applications rights patents related compounds products technology risk however issued patents enforceable provide adequate protection pending patent applications result issued patents patent applications confidential least period time sometimes united states patent issues result may know competitors filed patent applications technology covered pending applications first invent technology subject patent applications competitors may filed patent applications received patents may obtain additional patents proprietary rights block compete patents patent filings china certain asian countries covering forms adefovir dipivoxil active ingredient hepsera asia major market therapies hbv indication hepsera developed may obtain patents certain products many years marketing approval obtained products patents limited life may begin run prior commercial sale related product commercial value patent may limited however may able apply patent term extensions addition patents may provide adequate protection certain countries africa asia including china competitors may file patent applications covering technology may participate interference proceedings litigation determine right patent litigation interference proceedings expensive even ultimately successful part approval process products fda determined products would granted exclusivity period manufacturers applications approval generic versions product granted generic manufactures often wait challenge patents protecting products granted exclusivity one year prior end exclusivity period near end exclusivity periods granted products patents may subject challenges may need spend significant resources defend may able defend patents successfully success depends large part ability operate without infringing upon patents proprietary rights third parties infringe patents others may prevented commercializing products may required obtain licenses third parties may able obtain alternative technologies required license reasonable terms fail obtain licenses alternative technologies may unable develop commercialize products addition use significant proprietary technology rely unpatented trade secrets proprietary knowhow protect certain aspects production technologies trade secrets may become known independently discovered competitors may face significant liability resulting products may covered insurance successful claims could materially reduce earnings testing manufacturing marketing use commercial products well products development involve substantial risk product liability claims claims may made directly consumers healthcare providers pharmaceutical companies others although maintain product liability insurance successful product liability claim us may covered insurance could require us pay amounts beyond provided insurance either could impair financial condition ability clinically test market products expensive litigation may reduce earnings named defendant number lawsuits regarding use average wholesale price reimbursement rates medicaid also named lawsuits alleging violations federal securities laws adverse results lawsuits could result material damages could significantly reduce earnings cash flows changes effective income tax rate could reduce earnings various factors may favorable unfavorable effects effective income tax rate factors include limited interpretations existing tax laws changes tax laws rates future levels research development spending changes accounting rules future levels capital expenditures changes mix earnings various tax jurisdictions operate changes overall levels pretax earnings impact income tax provision resulting abovementioned factors may significant could negative impact results operations recently adopted changes accounting stock options may affect earnings financial accounting standards board fasb recently issued statement financial accounting standards revised sharebased payment sfas r required implemented third quarter provides new guidance accounting stock options new accounting guidance required record additional compensation expense related stock options equity incentives although currently evaluating various option valuation methodologies including blackscholes method binomial method methods allowed fas r impact earnings resulting new standard significant may negative impact results operations item properties corporate headquarters including principal executive offices research facilities located foster city california location approximately square feet space proximately located buildings currently occupy buildings also tenant occupying remaining buildings addition lease two office buildings approximately square feet space house commercial clinical development activities leases two buildings expire june respectively gilead option renew two fiveyear terms addition june may gilead option purchase two buildings specified amountswe also occupy facilities san dimas california location lease approximately square feet space houses research development activities manufacturing certain administrative functions leases expire november renewal options present addition lease adjacent warehouse facility square feet space use product distribution administrative functions lease expires november renewal options durham north carolina lease approximately square feet administrative office laboratory space sublease approximately square feet third parties lease expires october gilead option renew lease two sevenyear terms addition lease approximately square feet space aggregate sales marketing regulatory finance information technology human resource operations europe australia including prepaid year lease square foot manufacturing distribution facility ireland leases various expiration dates believe facilities adequate suitable least current nearterm future needs item legal proceedings complaints following cases allege large number defendants including gilead overcharged governmental entity named plaintiff pharmaceutical products furnished participants medicaid program general complaints assert claims federal state law except alabama state action includes state law claims seek treble damage attorneys fees litigations preliminary stage possible predict outcome indeed date gilead served process cases except county westchester v abbott laboratories et al intend defend cases vigorously outcome cases predicted time amounts accrued county westchester v abbott laboratories et al pending part multidistrict litigation united states district court district massachusetts lawsuit filed gilead approximately defendants august amended include approximately defendants january city new york v abbott laboratories et al pending part multidistrict litigation united states district court district massachusetts lawsuit filed gilead approximately defendants august amended approximately defendants january county rockland v abbott laboratories et al pending part multidistrict litigation united states district court district massachusetts lawsuit originally name gilead defendant amended include claims gilead well approximately defendants january state alabama v abbott laboratories et al pending circuit court montgomery county alabama lawsuit filed gilead approximately defendants january purported class action complaint filed november united states district court northern district california gilead certain executive officers complaint alleges defendants violated federal securities laws specifically sections b securities exchange act rule b securities exchange commission making certain allegedly false misleading statements omissions plaintiff seeks unspecified damages behalf purported class purchasers gileads securities period july october similar actions subsequently filed court issued order consolidating lawsuits single action december february court issued order appointing lead plaintiffs consolidated action april lead plaintiffs behalf purported class filed consolidated amended complaint june gilead individual defendants filed motion dismiss consolidated amended complaint january court granted defendants motion dismiss leave amend december two purported shareholder derivative lawsuits filed individual shareholders behalf gilead directors certain executive officers superior court state california county san mateo alleging among things defendants violated california corporations code breached fiduciary duties gilead gilead named nominal defendant plaintiffs seek unspecified damages behalf gilead connection alleged insider trading period july october defendants alleged breach fiduciary duties abuse control waste mismanagement two cases consolidated single action january third similar case filed february later consolidated prior two cases plaintiffs filed consolidated complaint amended two times recently november gilead demurred consolidated complaint court granted demurrer december plaintiffs filed motion leave file third consolidated amended complaint january court granted plaintiffs motion rendering complaint operative complaint intend demur complaint trial scheduled june also party various legal actions arose ordinary course business believe legal actions material adverse impact business results operations financial position item submission matters vote security holders matters submitted vote securities holders quarter ended december part ii item market registrants common equity related stockholder matters common stock traded nasdaq stock market symbol gild following table sets forth periods indicated high low intraday sale prices per share common stock nasdaq stock market prices represent quotations among dealers without adjustments retail markups markdowns commissions may represent prices actual transactions high low first quarter second quarter third quarter fourth quarter first quarter second quarter third quarter fourth quarter september implemented twoforone stock split form stock dividends share per share amounts periods presented restated reflect stock split february shares common stock outstanding held approximately stockholders record paid cash dividends common stock since inception anticipate paying foreseeable future item selected financial data gilead sciences inc selected consolidated financial data thousands except per share data year ended december consolidated statement operations data total revenues purchased inprocess research development total costs expenses income loss operations gain sale oncology assets provision benefit income taxes income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss amounts per common sharebasic income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss per sharebasic shares used per share calculationbasic amounts per common sharediluted income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss per sharediluted shares used per share calculationdiluted gilead sciences inc selected consolidated financial data continued december consolidated balance sheet data cash cash equivalents marketable securities working capital total assets longterm obligations convertible debt accumulated deficit total stockholders equity gilead recorded gain million related warrants eyetech completed initial public offering also recorded makewhole payment million related redemption million convertible senior debt gilead completed acquisition net assets triangle aggregate purchase price million approximately million purchase price allocated purchased inprocess research development also recorded income tax benefit million related reduction valuation allowance certain net deferred tax assets sold shares osi common stock recognized loss sale marketable securities million shares partial consideration sale oncology assets completed sale oncology assets related technology osi pharmaceuticals inc recorded nonoperating gain million also recorded nonoperating gain million sale percent interest proligo gilead adopted statement financial accounting standards nos collectively referred sfas accounting derivative instruments hedging activities first quarter change accounted change accounting principle effective first quarter gilead adopted secs staff accounting bulletin sab revenue recognition financial statements change also accounted change accounting principle february march september gilead implemented twoforone stock splits form stock dividend share per share amounts periods presented restated reflect stock splits cash dividends declared paid common stock item managements discussion analysis financial condition results operations executive summary operating results marked another year growth total revenues reaching billion higher ending cash cash equivalents marketable securities billion driven large part operating cash flows million year although several factors contributed improved financial performance two important drivers continued growth experienced hiv products portfolio comprised viread emtriva truvada well maintenance ambisome revenues amidst increasing competition given increased international sales favorable foreign currency environment europe viread sales increased year year comprised total product sales august launched truvada coformulation viread emtriva united states began launching truvada european union following regulatory approval february time depending treatment regimens prescribed physicians expect see truvada sales partially replace product sales viread emtriva increase future sales hiv products entered joint venture collaboration agreement bms december develop commercialize fixeddose combination gileads truvada bms sustiva united states understanding importance clear view wholesalers channel inventory signed inventory management agreements three major us wholesalers keeping strategy active product acquisition inlicensing rounded entering collaboration agreements area hcv operating results impacted acquisition assets triangle january completed acquisition expand antiviral pipeline triangle development stage company particular focus potential therapies hiv including aids hbv aggregate purchase price million included cash paid million fair value stock options assumed million direct transaction costs million employee related costs million approximately million consideration paid allocated purchased inprocess research development represented fair value triangles incomplete research development programs yet reached technological feasibility alternative future use acquisition date result transaction related purchased inprocess research development charge operating loss million acquisition important us compounds acquired also opportunity provided us create truvada coformulation viread emtriva single pill dosed day see note consolidated financial statements information triangle acquisition september gilead completed twoforone stock split effected form stock dividend stockholders record august accordingly share per share amounts periods presented restated reflect stock split addition certain prior year amounts also reclassified conform current year presentation managements discussion analysis read conjunction consolidated financial statements notes included elsewhere report forwardlooking statements risk factors following discussion contains forwardlooking statements involve risks uncertainties risk factors discussion read conjunction consolidated financial statements notes included elsewhere report critical accounting policies estimates judgments discussion analysis financial condition results operations based upon consolidated financial statements prepared accordance accounting principles generally accepted united states preparation financial statements requires us make estimates judgments affect reported amounts assets liabilities revenues expenses related disclosures ongoing basis evaluate estimates including related revenue recognition allowance doubtful accounts inventories clinical trial accruals tax provision base estimates historical experience various marketspecific assumptions believed reasonable circumstances results form basis making judgments carrying values assets liabilities readily apparent sources actual results however may differ significantly estimates believe following critical accounting policies reflect significant judgments estimates used preparation consolidated financial statements revenue recognitionwe recognize revenue product sales persuasive evidence arrangement exists delivery customer occurred price fixed determinable collectibility reasonably assured record estimated reductions revenue expected returns expired products distributor fees government rebate programs medicaid reimbursements customer incentives cash discounts prompt payment estimates distributor fees based contractually determined fixed percentages sales estimates government rebate programs cash discounts based contractual terms historical utilization rates expectations regarding future utilization rates programs estimates product returns including new products based ongoing analysis industry historical return patterns includes monitoring feedback receive sales force regarding customer use satisfaction reviewing inventory data available us us wholesaler inventory management agreements assist us monitoring channel inventory levels purchase thirdparty data monitor prescriptions well new products review long shelf life products sold similar channels monitor activities clinical trials key competitors assess potential impact future sales return expectations necessary expected returns marketed drugs generally low shelf life products ranges months truvada months ambisome viread united states conditions become competitive markets served drugs circumstances change may take actions increase product return estimates may offer additional customer incentives would result incremental reduction future revenue time return estimate changed new incentives offered contract revenue research development recorded performance occurs earnings process completed based performance requirements contract nonrefundable contract fees performance obligations exist continuing involvement gilead recognized earlier payments received collection reasonably assured revenue nonrefundable upfront license fees milestone payments continue involvement development collaboration obligation supply product recognized performance occurs obligations completed accordance specific terms gileads obligations types arrangements revenue recognized manufacturing obligation fulfilled ratably development period revenue associated substantive atrisk milestones recognized based upon achievement milestones defined respective agreements advance payments received excess amounts earned classified deferred revenue allowance doubtful accounts also maintain allowance doubtful accounts estimated losses resulting inability customers make required payments allowance based analysis several factors including limited contractual payment terms historical payment patterns customers individual customer circumstances analysis days sales outstanding customer geographic region review local economic environment potential impact government funding reimbursement practices financial condition customers economic environment operate deteriorate resulting inability make payments additional allowances may required allowance doubtful accounts balance percentage total accounts receivable materially change december december believe allowance doubtful accounts adequate cover anticipated losses current conditions however significant deterioration factors especially respect government funding reimbursement practices european market could materially change expectations result increase allowance doubtful accounts inventories write inventory based historical review quantity bad batches experienced manufacturing process expectations production inventory levels also perform quality control reviews individual raw material batches generally record inventory writeoffs based estimated obsolescence risk competition primarily shelf life products long however current assumptions future production inventory levels demand competition change actual market conditions less favorable projected management inventory writedowns may required could negatively impact product gross margins results operations clinical trial accruals record accruals estimated clinical preclinical study costs clinical preclinical studies performed third party contract research organizations cros costs significant component research development expenses incurred million million million respectively cro costs accrue costs clinical studies performed cros straightline basis term service period adjust estimates required based upon ongoing review level effort actually incurred cro initially estimate work performed contracts occurs ratably periods expected milestone event total contract completion date expected completion dates estimated based upon terms contracts past experience similar contracts estimates may may match actual services performed organizations determined patient enrollment levels measures activities specified contract result validate accruals quarterly written vendor confirmations detailed reviews activities performed significant contracts based upon results validation processes assess appropriateness accruals make adjustments deem necessary ensure expenses reflect actual effort incurred cros generally significant portion total costs associated start activities trial patient enrollment gilead extensively outsources clinical trial activities usually performs small portion startup activities inhouse result cros typically perform total startup activities trials including document preparation site identification screening preparation prestudy visits training program management budgeted basis costs typically total contract value actual basis percentage range significantly wider many contracts either expanded reduced scope compared original budget startup costs particular trial change significantly startup costs usually occur within months contract established milestone event driven nature remaining activities related costs patient monitoring administration generally occur ratably throughout life individual contract study contracts negotiated fixed unit prices vary length six months single dose phase study two years complex phase study average length contract upper end range order provide long term safety efficacy data support commercial launches viread truvada hepsera emtriva december differences actual estimated activity levels particular study significant enough require material adjustment material cro contracts terminable us upon written notice gilead generally liable actual effort expended cro point time contract regardless payment status amounts paid advance services performed refunded contract terminated however management receive complete accurate information vendors underestimated activity levels associated study given point time would record additional potentially significant research development expenses future periodstax provision develop income tax provision including deferred tax assets liabilities based significant management judgment evaluate realizibility deferred tax assets quarterly basis record valuation allowance reduce deferred tax assets amounts likely realized consider future taxable income ongoing tax planning strategies historical financial performance assessing need valuation allowance expect realize deferred tax assets previously recorded valuation allowance would reduce valuation allowance period determination first made adjustment made fourth quarter determined likely certain deferred tax assets would realized therefore released related valuation allowance resulted income tax benefit approximately million million respectively similarly determine would able realize part deferred tax assets valuation allowance would increase valuation allowance period determination first made future effective income tax rate may affected factors changes tax laws rates changes interpretation laws impact accounting employee stock options beginning second half overall changes future levels earnings research development capital spending management discussed development selection critical accounting policies audit committee gileads board directors audit committee reviewed disclosure presented relating results operations total revenues total revenue billion million million included total revenue product sales royalty revenue contract revenue includes revenue earned research development rd manufacturing collaborations product sales product sales consisted following thousands change change viread emtriva truvada total hiv products ambisome total product sales product sales increased compared compared due primarily increase volume sales within hiv products significant percentage product sales continue denominated foreign currencies use forward contracts hedge percentage forecasted international sales primarily denominated euro reduces eliminate fluctuations sales due changes foreign currency exchange rates losses revenue hedges reduced increases product sales million million million due fluctuations exchange rates however product sales mainly viread ambisome benefitted overall primarily increases exchange rates euro british pound comparison us dollar million comparing million comparing prior experienced significant fluctuations us distribution channel inventory levels due speculative purchasing major wholesalers result experienced increased quarter quarter sales volatility purchasing patterns order help alleviate fluctuations july entered inventory management agreements imas amerisourcebergen drug corporation cardinal health inc mckesson corporation three major pharmaceutical wholesalers distribute percent portfolio products sell united states agreements implemented limit speculative buying help ensure wholesaler purchasing consistent customer demand predictable agreements agreed pay wholesalers fee exchange product distribution inventory management services market research information return goods processing assistance counterfeit product detection services fees recorded reduction product sales consolidated statements operations additionally terms agreements wholesaler agreed exceed specified maximum levels inventory hand end december believe three major wholesalers inventories onhand gilead products less one months supply compliance contractually specified levels viread emtriva truvada approved sale united states october july august respectively viread emtriva approved sale european union february october respectively sales viread total product sales respectively viread sales million us sales increase versus million international sales increase versus viread sales million us sales increase versus million international sales increase versus since emtrivas introduction july sales increased significantly million million also since august truvada approved sale united states product sales totaled million december total hiv product sales million higher compared due favorable european currency environment majority relates viread sales believe product sales mix changes patients currently taking viread andor emtriva switching truvada looking hiv products sales collectively relevant basis periodoverperiod comparison sales hiv products percentage total product sales respectively expect sales hiv products billion billion full year sales ambisome total product sales respectively hiv hbv product sales continue increase ambisome sales decreasing percentage total product sales ambisome sales million us sales decrease versus million international sales increase versus ambisome sales million us sales decrease versus million international sales increase reported ambisome sales million higher due favorable currency environment compared volume basis ambisome sales united states decreased sales volume europe increased slightly compared analyzing decrease us sales important note us product sales decreased comparing volume decreased discussion us ambisome sales relates solely sales ambisome fujisawa recorded manufacturing cost due greater manufacturing efficiencies per unit manufacturing cost ambisome decreased thereby decreasing revenuesreported sales fujisawa royalties earn sales ambisome fujisawa discussed continuing competition expect ambisome sales range million million royalty revenue recorded royalty revenues million compared million million threeyear period significant source royalty revenue resulted sales tamiflu roche sales ambisome united states fujisawa copromotion arrangement us royalty revenues earned sales tamiflu million million million respectively royalty revenues earned sales ambisome fujisawa million million million respectively difficult estimate third party product sales record royalty revenue roche one quarter arrears due severe influenza epidemic united states late early royalty revenues increased substantially first second quarters increased awareness discussion supply influenza treatments increased roches sales tamiflu consequently royalties third fourth quarters contract revenue total contract revenue million compared million million contract revenue consisted primarily million research milestone revenue earned eyetech pharmaceuticals included million net milestone payments earned upon filing new drug applications eyetech europe united states macugen pegaptanib sodium injection primary source contract revenue consisted million license fees earned conjunction licensing agreement eyetech macugen contract revenue primarily consisted million due licensing selex process patent estate archemix due collectibility concerns recognized cash basis million milestone payments roche european prophylaxis treatment approvals tamiflu december completed sale oncology assets osi terms agreement entitled additional payments osi million either cash combination cash osi stock osi reaches certain development milestones nx advanced oncology product candidates sold osi related manufacturing agreement produce nx gs l two liposomal products included sales manufacturing facility san dimas california recognized million million million respectively contract revenue manufacturing agreement cost goods sold product gross margins following table indicates cost goods sold product gross margins thousands change change total product sales cost goods sold gross margin percentage gross margin relatively flat positive impact improvements certain manufacturing processes favorable foreign currency environment offset changes product sales mix comparing gross margin improved primarily due change product mix viread higher margin product contributed significantly net product sales changes foreign currency exchange rates impact gross margins since price products currency country products sold significant majority manufacturing costs us dollars example increase value foreign currencies relative us dollar positively impact gross margins since manufacturing costs remain approximately revenues translated us dollars increase although weakening us dollar positively impacted gross revenues gross margins full effect foreign currency exchange rates moderated hedging program forecasted international sales except potential impact unpredictable uncontrollable changes exchange rates relative us dollar mix product sales various hiv products hepsera ambisome expect gross margins consistent within range research development expenses following table summarizes research development expenses major components thousands change change research clinical development pharmaceutical development total three major categories research development rd expenses consist personnel costs including salaries benefits clinical studies performed contract research organizations materials supplies overhead allocations consisting various support facilities related costs research costs typically consist preclinical toxicology work clinical development costs include phase clinical trials well expanded access programs pharmaceutical development costs consist product formulation chemical analysis prior clinical development consisted clinical trial expenses phases phase united states phase european clinical trials included sales general administrative sga order better reflect nature european phase clinical trials began recording clinical trial expenses research development order consistent current year presentation million million expenses reclassified selling general administrative research development expenses years ended december respectively million increase rd expenses primarily attributable increased salaries million due largely higher headcount increased contract research organization costs million associated increased clinical activities well million research license fees paid us relation hepatitis c collaboration agreements effective fourth quarter new collaborations entered achillion genelabs required us pay aggregate license fees million expensed rd underlying technology alternative future use increase rd activity partially offset decrease spending due discontinuation two programs gs gs focused thedevelopment certain hiv investigational products also important note rd expenses included reimbursement gilead million settlement contractual dispute vendor million increase rd spending versus primarily attributable increased salaries million due largely higher headcount increased clinical supplies costs million increased clinical trials costs associated development emtriva truvada coformulation viread emtriva also mentioned settled contractual dispute vendor resulted reimbursement us million recorded research development expense expect rd expenses approximately million million estimated increase expenses levels reflects increased spending internal research development efforts well costs associated postmarketing studies support products excludes expenses may incur associated potential collaborations strategic acquisitions including license milestone fees cost sharing arrangements impact accounting employee stock based compensation beginning second half industry reports indicate biopharmaceutical company generally takes years average years research develop bring market new prescription medicine united states averages generally consistent projects undertake internally although recent product development timelines slightly accelerated basis drug development united states process includes several steps defined fda process begins filing ind successful allows opportunity clinical study potential new medicine clinical development typically involves three phases study phase generally accounts average seven years drugs total development time significant costs associated clinical development phase trials tend longest largest studies conducted drug development process currently products development phase studies successful development products highly uncertain completion dates rd expenses vary significantly product difficult predict even successful development fda approval product undertake additional studies try expand products label market potential complete discussion risks uncertainties associated completing development products see risk factors affect gilead section item selling general administrative expenses following table highlights year year changes selling general administrative expenses thousands change change selling general administrative sga expenses year ended december million compared million year ended december includes reclassification phase iv clinical trial expenses incurred rd million significant increase expenses compared primarily due increased salaries million due largely higher headcount increased consulting fees million related sarbanesoxley compliance business strategy consulting well increased costs million relating speakers programs grants journal advertising remainder increase sga expenses compared due increased global marketing efforts increased infrastructure required support growth business part infrastructure investments implemented reorganization sales marketing functions newly created commercial division conjunction reorganization created filled new position executive vicepresident commercial operations responsibility global commercial operations strategy product portfolio increase expenses compared includes reclassification phase iv clinical trial expenses rd million primarily due increased salaries million due largely higher headcount increase hedging costs million increased costs million relating marketing meetings grants well increased general directors officers insurance million remainder increase sga expenses due global sales marketing efforts including expansion us european sales forces increased infrastructure required support growth business expect sga expenses approximately million million primarily due anticipated launch costs truvada european union well ongoing investment global commercial organization hiring promotional programs excludes expenses may incur associated potential collaborations strategic acquisitions impact applying new standard accounting employee stock based compensation beginning second half purchased inprocess research development connection acquisition net assets triangle completed january recorded purchased inprocess research development expenses million first quarter charge due triangles incomplete research development programs yet reached technological feasibility alternative future use acquisition date value purchased inprocess research development determined estimating related future net cash flows using present value risk adjusted discount rate discount rate significant assumption based estimated weighted average cost capital adjusted upward risks associated projects acquired projected cash flows acquired projects based estimates revenues operating profits related projects considering stage development potential product acquired time resources needed complete development approval product life potential commercialized product associated risks including inherent difficulties uncertainties developing drug compound including obtaining fda regulatory approvals risks related viability potential alternative treatments future target markets summary programs acquisition date updated subsequent developments february follows estimated acquisition date fair value program description status development millionsemtricitabine hiv nucleoside analogue four phase studies completed shown prior acquisition date us inhibitor hiv replication marketing approval received patients fda july emtriva european union approval received european commission october emtricitabinetenofovir df fixeddose acquisition date work fixed dose combination coformulation tenofovir commenced potential co hiv therapy emtricitabine formulation except extent work emtricitabine single agent progressing march applications marketing approval submitted united states european union august marketing approval united states received fda truvada fixeddose coformulation tenofovir emtricitabine marketing approval european union received february amdoxovir hiv purine dioxolane program phase trials nucleoside may offer acquisition date terminated advantages licensing agreement emory marketed nucleosides university university activity georgia research foundation inc drug resistant development discontinued viruses exhibited patients hiv infection clevudine hbv pyrimidine nucleoside program phase trials analogue acquisition date august shown inhibitor licensing agreement bukwang hbv replication patients pharm ind co ltd terminated chronically infected development discontinued hbv emtricitabine hbv inhibitor hbv one phase trial completed replication patients december chronically infected hbv asset impairment recorded asset impairment charge million certain longlived assets primarily leasehold improvements manufacturing laboratory equipment noncash charge driven decision december terminate liposomal research development activities san dimas discontinue daunoxome product line impairment based analysis undiscounted cash flows generated affected assets compared carrying value carrying value exceeded related estimated undiscounted cash flows wrote carrying value long lived assets estimated fair value subsequent decision discontinue daunoxome product line received unanticipated requests europe asking gilead reconsider selling daunoxome result requests management decided continue selling product certain countries still evaluating supply sales strategy respect daunoxome accordance us generally accepted accounting principles new cost basis impaired assets adjusted new facts circumstances gain loss marketable securities pursuant agreement eyetech entered march received warrant purchase shares eyetech series b convertible preferred stock exercisable price per share january eyetech completed initial public offering common stock time adjusted fair value warrant resulting gain million time fair value warrant estimated using blackscholes valuation model volatility rate discount rate end first quarter exercised warrant net basis using shares eyetech common stock consideration exercise price subsequently held shares eyetech common stock second quarter sold eyetech shares owned realized gain approximately million included interest income net year ended december july sold remaining shares osi common stock approximately million shares partial consideration sale oncology assets osi december time recorded fair market value approximately million connection sale remaining shares recognized nonoperating loss approximately million year ended december makewhole payment debt redemption october gilead called redemption outstanding convertible senior notes due december november convertible senior notes called provisional redemption based upon market price gilead common stock exceeding certain thresholds aggregate principal amount outstanding notes million convertible senior notes redeemable redemption price equal principal amount notes plus cash payment equal accrued unpaid interest redemption date cash makewhole payment equal per principal value notes less interest actually paid accrued unpaid date issuance notes redemption date interest convertible senior notes ceased accrue redemption date remaining right holders thereafter receive redemption payment including accrued unpaid interest redemption date makewhole payment alternatively note holders could elect convert notes shares gilead common stock price per share shares gilead common stock per principal amount notes holders substantially ofthe outstanding notes converted notes shares gileads common stock prior november redemption date result conversions shares common stock issued note holders connection redemption gilead paid aggregate makewhole payments million note holders interest income net recorded interest income million compared million million increase compared primarily attributable higher cash balances yields past year decrease compared attributable significant decline interest rates lower average cash balance due acquisition net assets triangle purchase foster city campus partially offset positive cash flow operations interest income depend principally upon prevailing interest rates level cash cash equivalent marketable securities balances interest expense incurred interest expense million compared million million decrease primarily due conversion million convertible subordinated debt shares common stock december outstanding debt consisted million convertible senior debt issued december november converted convertible senior notes significant increase due full year interest million convertible senior notes issued december interest expense consisted primarily interest million convertible subordinated notes converted shares common stock december expect interest expense decrease compared primarily due conversion million convertible senior notes november provision benefit income taxes provision benefit income taxes million million million respectively effective income tax rate differs us federal statutory rate generally due state taxes offset recognition previously unbenefitted net operating losses tax credit carryforwards certain earnings taxed foreign tax rate jurisdictions lower tax rates us taxes provided earnings planned permanently reinvested outside united states tax benefit includes reversal valuation allowance certain deferred tax assets december concluded likely would realize portion benefit related deferred tax assets accordingly reduced valuation allowance assets recorded tax benefit million recognition deferred tax assets impact cash flows partially offsetting tax benefit income tax expense associated income earned foreign subsidiaries foreign losses benefitted lower tax rates nontax deductibility purchased inprocess research development significant net operating loss carryforwards used reduce us tax liability excluding benefit relating reversal valuation allowance write purchased inprocess research development effective tax rate income tax expense primarily associated income earned foreign subsidiaries significant net operating losses united states provision reduced change us income tax law law allowed net operating loss carryforward deductions offset alternative minimum taxable income resulting reduction us income tax recorded previous years million october american jobs creation act ajca signed law ajca allows deduction certain foreign earnings repatriated defined ajca may elect apply provision qualifying earnings repatriations fiscal started evaluation effects repatriation provision however expect able complete evaluation congress treasury department provide additional clarifying language key elements provision expect complete evaluation effects repatriation provision within reasonable period time following publication additional clarifying language range possible amounts considering repatriation provision zero million maximum amount allowable us defined ajca currently related potential range impact income taxes reasonably estimated liquidity capital resources cash cash equivalents marketable securities totaled billion december million december increase million primarily due net cash provided operations million proceeds issuances stock employee stock plans million partially offset capital expenditures million cash decrease million primarily due acquisition triangle net cash impact million purchase foster city campus million capital expenditures million partially offset proceeds issuance stock employee stock plans million working capital december billion compared billion december significant changes working capital included million decrease current deferred tax assets offset million increase accounts receivable million increase inventory million decrease current deferred tax assets primarily due utilization net operating losses tax credit carryforwards offset taxable income accounts receivable increase million primarily due increased sales viread united states europe sales new product truvada launched united states latter half million increase inventory primarily due increase purchase raw materials production viread truvada inventory meet increasing sales demand current liabilities increased million primarily due following million increase medicaid rebate obligations associated higher sales viread million increase deferred revenue primarily due royalties received roche million increase liability associated fair value forward currency contracts us dollar continued weaken european currencies million increase accounts payable primarily due increases raw material purchases support viread truvada sales growth million increase increased compensation costs employee benefits added headcount increase million distributors fees owed yet paid inventory management agreements entered july increase current liabilities partially offset million decrease accrued clinical preclinical expenses result decreasing activity associated clinical trial programs viread hepsera towards end made capital expenditures million compared million million expenditures primarily domestic international facilities improvements including approximately million associated completion pilot plant foster city used todevelop drug processes prepare materials supply clinical trials well additional spending laboratory manufacturing equipment accommodate growth capital expenditures related research development million spent million spent million spent expect capital spending million million due increased infrastructure needs higher rd spending believe existing capital resources supplemented cash generated operations adequate satisfy capital needs foreseeable future future capital requirements depend many factors including commercial performance current future products progress scope research development efforts including preclinical studies clinical trials cost timing outcome regulatory reviews expansion sales marketing capabilities administrative expenses possibility acquiring manufacturing capabilities additional office facilities possibility acquiring companies new products establishment additional collaborative relationships companies defense costs associated settlements adverse results litigation may future require additional funding could form proceeds equity debt financings universal shelf registration statement filed december potential issuance million securities additional collaborative agreements corporate entities funding required assure available favorable terms subsidiaries established variety subsidiaries various countries purpose conducting business locations subsidiaries consolidated financial statements variable interest entities unconsolidated financial statements also involved nonexchange traded commodity contracts accounted fair value commercial commitments related parties except employee loans contractual obligations contractual obligations form capital operating leases noncancelable raw material supply arrangements clinical research organization contracts following table summarizes contractual obligations december thousands payments due period less one contractual obligations total year years years years capital lease obligations operating lease obligations capital commitments inventory purchase obligations clinical trials total december firm capital project commitments approximately million relating facilities improvement addition budgeted significant capital expenditures mainly due anticipated increased infrastructure needs higher rd spending may capital spending future years december firm commitments purchase active pharmaceutical ingredients amounts disclosed represent minimum purchase requirements actual purchases may differ significantly amounts december several clinical studies various clinical trial phases significant expenditures contract research organizations although contracts cancelable generally cancelled contracts amounts reflect commitments based existing contracts reflect future modifications existing contracts anticipated potential new contracts recent accounting pronouncement december fasb issued sfas revised sharebased payment sfas r revision sfas sfas r supercedes apb amends sfas statement cash flows sfas r requires sharebased payments employees directors including grants stock options recognized statement operations based fair values beginning first interim annual period june early adoption permitted pro forma disclosures previously permitted sfas longer alternative financial statement recognition expect adopt sfas r third quarter fiscal beginning july sfas r must determine appropriate fair value model used valuing sharebased payments amortization method compensation cost transition method used date adoption transition methods include prospective retroactive adoption options retroactive options prior periods may restated either beginning year adoption periods presented prospective method requires compensation expense recorded unvested stock options restricted stock beginning first quarter adoption sfas r retroactive methods would record compensation expense unvested stock options restricted stock beginning first period restated currently evaluating requirements sfas r well option valuation methodologies related employee director stock options employee stock purchase plan although yet determined method adoption effect adoptingsfas r expect adoption sfas r material impact consolidated results operations earnings per share impact adoption sfas r predicted time depend among things levels sharebased payments granted future method adoption option valuation method used sfas r also requires benefits tax deductions excess recognized compensation cost reported financing cash flow rather operating cash flow required current literature requirement reduce net operating cash flows increase net financing cash flows periods adoption estimate amounts future depend among things employees directors exercise stock options amount operating cash flows recognized prior periods related tax deductions million million million respectively current estimates option values using blackscholes method may indicative results valuation methodologies ultimately adopted gilead item quantitative qualitative disclosures market risk foreign currency exchange risk operations include manufacturing sales activities united states well sales activities europe australia result financial results could significantly affected factors changes foreign currency exchange rates weak economic conditions foreign markets distribute products operating results exposed changes exchange rates us dollar various foreign currencies significant euro british pound australian dollar us dollar strengthens currencies relative value sales made respective foreign currency decreases conversely us dollar weakens relative amounts sales increase overall net receiver foreign currencies therefore benefit weaker us dollar adversely affected stronger us dollar relative foreign currencies transact significant amounts business mitigate impact changes currency exchange rates cash flows foreign currency sales transactions enter foreign exchange forward contracts hedge foreign currencydenominated net monetary assets liabilities significant percentage product sales denominated foreign currencies increases value us dollar foreign currencies past reduced future may reduce us dollar return sales negatively impact financial condition prior hedge exposure impact fluctuating foreign exchange rates forecasted sales january began use forward contracts hedge percentage forecasted international sales primarily denominated euro currency recent years due weakening us dollar foreign currency exchange fluctuations positively impacted product sales gross margin however full impact favorable foreign currency environment moderated hedge contracts entered following table summarizes notional amounts average currency exchange rates fair values open foreign exchange forward contracts december contracts maturities one year less average rates stated terms amount foreign currency per us dollar fair values represent estimated settlement amounts december notional amounts fair values us dollars thousands fair value currency notional amount average rate december british pound euro australian dollar total notional amount million fair value million open foreign exchange forward contracts december compares total notional amount million fair value million open foreign exchange forward contracts december significant increase outstanding contracts primarily attributed projected increase revenues forecast periods interest rate risk portfolio availableforsale investment securities fixedrate liabilities create exposure interest rate risk respect investment portfolio adhere investment policy requires us limit amounts invested securities based duration industry group investment type issuer except securities issued us government goals investment policy order priority follows safety preservation principal diversification risk liquidity investments sufficient meet cash flow requirements competitive aftertax rate return following table summarizes expected maturities average interest rates fixedrate interestbearing assets fixedrate liabilities december dollars thousands fair value years ending december december thereafter total assets availableforsale securities average interest rate liabilities longterm obligations including current portion average interest rate longterm obligations consist capital leases operating leases net noncancelable subleases interest portion payments due included international credit riskour accounts receivable balance december million compared million december million december growth accounts receivable balances primarily due higher product sales viread united states europe certain countries payments typically slow primarily greece italy portugal spain accounts receivable balances significant cases slow payment practices reflect pace governmental entities reimburse customers turn may increase credit risk related certain customers sales customers countries tend relatively slow paying past increased future may increase average length time accounts receivable outstanding december past due accounts receivable greece italy portugal spain totaled approximately million approximately million days past due date experienced significant losses respect collection accounts receivable believe substantially accounts receivable balances collectible perform credit evaluations customers financial condition generally required collateral item financial statements supplementary data financial statements required item set forth beginning report incorporated herein reference item changes disagreements accountants accounting financial disclosure applicable item controls procedures evaluation disclosure controls procedures evaluation december carried supervision participation management including chief executive officer chief financial officer effectiveness design operation disclosure controls procedures defined sec rules controls procedures company designed ensure information required disclosed company reports files securities exchange act exchange act recorded processed summarized reported within required time periods based upon evaluation chief executive officer chief financial officer concluded disclosure controls procedures effective b managements report internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting term defined securities exchange act rule af internal control system designed provide reasonable assurance regarding preparation fair presentation financial statements external purposes accordance generally accepted accounting principles internal control systems matter well designed inherent limitations provide reasonable assurance objectives internal control system met supervision participation management including principal executive officer principal financial officer conducted evaluation effectiveness internal control financial reporting using criteria set forth committee sponsoring organizations treadway commission coso internal control integrated framework based evaluation concluded internal control financial reporting effective december ernst young llp independent registered public accounting firm audited consolidated financial statements included herein issued audit report assessment internal control financial reporting c changes internal control financial reporting management including chief executive officer chief financial officer evaluated changes internal control financial reporting occurred quarter ended december concluded change quarter materially affected reasonably likely materially affect internal control financial reporting item b information none part iii item directors executive officers registrant information required item concerning directors executive officers incorporated reference sections definitive proxy statement filed sec pursuant regulation connection annual meeting proxy statement headings nominees executive officers board directors audit committee compliance section securities exchange act gileads written code ethics applies directors employees including executive officers code ethics available gileads website httpwwwinvestorsgileadcom changes waivers code ethics disclosed website item executive compensation information required item incorporated reference sections proxy statement headings executive compensation compensation committee report item security ownership certain beneficial owners management related stockholder matters information required item incorporated reference section proxy statement heading security ownership certain beneficial owners management item certain relationships related transactions information required item incorporated reference sections proxy statement headings compensation committee interlocks insider participation certain transactions executive compensationitem principal accountant fees services information required item incorporated reference sections proxy statement heading principal accountant fees services part iv item exhibits financial statement schedules following documents filed part index list financial statements reports independent registered public accounting firm audited consolidated financial statements consolidated balance sheets consolidated statements operations consolidated statement stockholders equity consolidated statements cash flows notes consolidated financial statements schedule ii included report schedules omitted required required information included financial statements notes thereto exhibits following exhibits filed herewith incorporated reference exhibit exhibit footnote number description document asset purchase agreement registrant osi pharmaceuticals inc dated november agreement plan merger among registrant simbolo acquisition sub inc wholly owned subsidiary registrant triangle pharmaceuticals inc dated december amended restated certificate incorporation registrant amended bylaws registrant amended restated march reference made exhibit exhibit amended restated rights agreement dated october registrant chasemellon shareholder services llc agreement plan merger dated february among registrant gazelle acquisition sub inc nexstar pharmaceuticals inc registration rights agreement dated december registrant goldman sachs co first amendment amended restated rights agreement dated october registrant mellon investor services llc form indemnity agreement entered registrant directors executive officers form employee proprietary information invention agreement entered registrant certain officers key employees registrants incentive stock option plan related agreements registrants supplemental stock option plan related agreements registrants employee stock purchase plan amended march registrants stock option plan amended restated april amended january amended january form nonqualified stock option issued certain executive officers directors letter agreement dated september registrant iocbrega exhibits certain confidential information omitted amendment agreement dated october registrant iocbrega related license agreements exhibits certain confidential information omitted amendment agreement dated december registrant iocbrega registrants nonemployee directors stock option plan amended january amended january development license agreement registrant f hoffmannla roche ltd hoffmannla roche inc dated september certain confidential information omitted nexstar pharmaceuticals incs incentive stock plan adopted february amended nexstar pharmaceuticals incs director option plan adopted july vestar inc stock option plan lease dated february registrant majestic mapa properties llc lease dated february registrant majestic mapa properties llc assignment royalty agreement dated december effective june vestar inc city hope national medical center agreement fujisawa usa inc vestar inc dated august amendment thereto dated may amendment agreement fujisawa usa inc vestar inc dated april fujisawa usa inc vestar inc certain confidential information omitted amendment agreement fujisawa usa inc registrant dated march agreement fujisawa usa inc vestar inc dated august lease dated july among registrant majestic realty co majesticmapa properties llc first amendment thereto dated march license distribution agreement dated september sumitomo pharmaceuticals co ltd nexstar pharmaceuticals inc certain confidential information omitted settlement agreement dated august among nexstar pharmaceuticals inc fujisawa usa inc liposome company inc certain confidential information omitted amendment dated april sumitomo pharmaceuticals co ltd nexstar pharmaceuticals inc license distribution agreement dated september sumitomo nexstar pharmaceuticals inc corporate plan retirement select planbasic plan document corporate plan retirement select planadoption agreement addendum gilead sciences inc deferred compensation plan licensing agreement dated april gilead world markets limited glaxo group limited employment agreement dated july gilead sciences inc sharon surreybarbari triangle pharmaceuticals inc stock incentive plan option agreement triangle pharmaceuticals inc daniel g welch dated august license agreement among triangle pharmaceuticals inc emory university university georgia research foundation inc compound amdoxovir dapd dated march license agreement triangle pharmaceuticals inc emory university coviracil ftc dated april exclusive license agreement among triangle pharmaceuticals inc glaxo group limited wellcome foundation limited glaxo wellcome inc emory university dated may settlement agreement among triangle pharmaceuticals inc emory university dr david w barry glaxo wellcome plc glaxo wellcome inc glaxo group limited wellcome foundation limited dated may first amendment license agreement triangle pharmaceuticals inc emory university dated may first amendment license agreement among triangle pharmaceuticals inc emory university university georgia research foundation inc dated july second amendment license agreement triangle pharmaceuticals inc emory university dated july supply manufacturing agreement triangle pharmaceuticals inc abbott laboratories dated july settlement exclusive license agreement among triangle pharmaceuticals inc shire biochem inc shire pharmaceuticals group plc emory university university georgia research foundation dated august second amendment license agreement among triangle pharmaceuticals inc emory university university georgia research foundation inc dated august manufacturing supply agreement gilead world markets ltd ppgsipsy sas entered january gilead sciences inc severance plan adopted effective january third amendment license agreement triangle pharmaceuticals inc emory university dated may lease agreement dated june th registrant gra associates limited llc premises located university drive durham north carolina master clinical commercial supply agreement dated january among gilead world markets ltd gilead sciences inc patheon inc toll manufacturing agreement dated august among gilead world markets ltd gilead sciences inc altana pharma oranienburg gmbh licensing agreement dated march amended may december april gilead sciences inc eyetech pharmaceuticals inc amendment licensing agreement dated may eyetech pharmaceuticals inc gilead sciences inc amendment licensing agreement dated december eyetech pharmaceuticals inc gilead sciences inc amendment licensing agreement dated august eyetech pharmaceuticals inc gilead sciences inc amendment dated may licensing agreement dated april glaxo group limited gilead world markets limited amendment dated january licensing agreement dated april glaxo group limited gilead world markets limited employment agreement dated april gilead sciences inc mark l perry gilead sciences inc equity incentive plan amended july collaboration agreement among gilead sciences inc gilead holdings llc bristol myers squibb company er squibb sons llc bristolmyers squibb gilead sciences llc dated december th amendment license agreement triangle pharmaceuticals inc emory university dated may subsidiaries registrant consent independent registered public accounting firm power attorney reference made signature section certification section certification section certification filed exhibit registrants annual report fiscal year ended december incorporated herein reference filed exhibit nexstar pharmaceuticals incs quarterly report form q quarter ended june incorporated herein reference filed exhibit registrants current report form k filed october incorporated herein reference filed exhibit registrants registration statement form amended incorporated herein reference filed exhibit registrants annual report fiscal year ended march incorporated herein reference filed exhibit registrants quarterly report form q quarter ended september incorporated herein reference filed exhibit registrants current report form k filed march incorporated herein reference filed exhibit nexstar pharmaceuticals incs fiscal year ended december incorporated herein reference filed exhibit nexstar pharmaceuticals incs fiscal year ended december incorporated herein reference filed exhibit nexstar pharmaceuticals incs form q quarterly period ended september incorporated herein reference filed exhibit nexstar pharmaceuticals incs fiscal year ended december incorporated herein reference filed march exhibit nexstar pharmaceuticals incs registration statement form file incorporated herein reference filed exhibit nexstar pharmaceuticals incs form q quarterly period ended september incorporated herein reference filed exhibit nexstar pharmaceuticals incs form q quarter ended june incorporated herein reference filed exhibit registrants fiscal year ended december incorporated herein reference filed exhibit registrants fiscal year ended december incorporated herein reference filed exhibit registrants current report form k filed january incorporated herein reference filed exhibit registrants quarterly report form q quarter ended june incorporated herein reference filed exhibit registrants quarterly report form q quarter ended september incorporated herein reference filed exhibit registrants fiscal year ended december incorporated herein reference filed exhibit registrants current report form k filed december incorporated herein reference filed exhibit registrants registration statement form filed january incorporated herein reference filed exhibit registrants registration statement form filed january incorporated herein reference filed exhibit triangle pharmaceuticals incs registration statement form amended incorporated herein reference filed exhibit triangle pharmaceuticals incs quarterly report form q quarter ended september incorporated herein reference filed exhibit triangle pharmaceuticals incs quarterly report form q quarter ended september incorporated herein reference filed exhibit triangle pharmaceuticals incs current report form k filed september incorporated herein reference filed exhibit triangle pharmaceuticals incs quarterly report form q quarter ended september incorporated herein reference filed exhibit registrants current report form k filed october incorporated herein reference filed exhibit registrants quarterly report form q quarter ended march incorporated herein reference filed exhibit registrants quarterly report form q quarter ended june incorporated herein reference filed exhibit registrants fiscal year ended december incorporated herein referencefiled exhibit registrants quarterly report form q quarter ended march incorporated herein reference filed exhibit registrants quarterly report form q quarter ended june incorporated herein reference filed exhibit registrants fiscal year ended december incorporated herein reference filed exhibit registrants fiscal year ended december incorporated herein reference certain confidential portions exhibit omitted means marking portions asterisk mark exhibit filed separately secretary sec without mark pursuant registrants application requesting confidential treatment rule b securities exchange act gilead sciences inc consolidated financial statements years ended december contents reports independent registered public accounting firm audited consolidated financial statements consolidated balance sheets consolidated statements operations consolidated statement stockholders equity consolidated statements cash flows notes consolidated financial statements report independent registered public accounting firm board directors stockholders gilead sciences inc audited accompanying consolidated balance sheets gilead sciences inc december related consolidated statements operations stockholders equity cash flows three years period ended december audits also included financial statement schedule listed item annual report financial statements schedule responsibility management gilead sciences inc responsibility express opinion financial statements schedule based audits conducted audits accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit includes examining test basis evidence supporting amounts disclosures financial statements audit also includes assessing accounting principles used significant estimates made management well evaluating overall financial statement presentation believe audits provide reasonable basis opinion opinion financial statements referred present fairly material respects consolidated financial position gilead sciences inc december consolidated results operations cash flows three years period ended december conformity us generally accepted accounting principles also opinion related financial statement schedule considered relation basic financial statements taken whole presents fairly material respects information set forth therein also audited accordance standards public company accounting oversight board united states effectiveness gilead sciences incs internal control financial reporting december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission report dated march expressed unqualified opinion thereon ernst young llp palo alto california march report independent registered public accounting firm board directors stockholders gilead sciences inc audited managements assessment included accompanying managements annual report internal control financial reporting included item gilead sciences inc maintained effective internal control financial reporting december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission coso criteria gilead sciences incs management responsible maintaining effective internal control financial reporting assessment effectiveness internalcontrol financial reporting responsibility express opinion managements assessment opinion effectiveness gilead sciences incs internal control financial reporting based audit conducted audit accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether effective internal control financial reporting maintained material respects audit included obtaining understanding internal control financial reporting evaluating managements assessment testing evaluating design operating effectiveness internal control performing procedures considered necessary circumstances believe audit provides reasonable basis opinion companys internal control financial reporting process designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles companys internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition companys assets could material effect financial statements inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate opinion managements assessment gilead sciences inc maintained effective internal control financial reporting december fairly stated material respects based coso criteria also opinion gilead sciences inc maintained material respects effective internal control financial reporting december based coso criteria also audited accordance standards public company accounting oversight board united states consolidated balance sheets gilead sciences inc december related consolidated statements operations stockholders equity cash flows three years period ended december related financial statement schedule report dated march expressed unqualified opinion thereon ernst young llp palo alto california march gilead sciences inc consolidated balance sheets thousands except per share amounts december assets current assets cash cash equivalents marketable securities accounts receivable net allowances december december inventories deferred tax assets prepaid expenses total current assets property plant equipment net noncurrent deferred tax assets noncurrent assets liabilities stockholders equity current liabilities accounts payable accrued clinical preclinical expenses accrued compensation employee benefits accrued liabilities deferred revenue longterm obligations due within one year total current liabilities longterm deferred revenue longterm obligations due one year convertible senior debt commitments contingencies stockholders equity preferred stock par value per share shares authorized none outstanding common stock par value per share shares authorized shares issued outstanding december respectively additional paidin capital accumulated comprehensive income loss deferred stock compensation accumulated deficit total stockholders equity see accompanying notes gilead sciences inc consolidated statements operations thousands except per share amounts year ended december revenues product sales royalty revenue contract revenue total revenues costs expenses cost goods sold research development selling general administrative purchased inprocess research development asset impairment total costs expenses income loss operations gain loss marketable securities makewhole payment convertible debt redemption interest income net interest expense income loss provision benefit income taxes provision benefit income taxes net income loss net income loss per sharebasic shares used per share calculationbasic net income loss per sharediluted shares used per share calculationdiluted see accompanying notes gilead sciences inc consolidated statement stockholders equity thousands accumulated additional comprehensive total common stock paidin income deferred stock accumulated stockholders shares amount capital loss compensation deficit equity balance december net income unrealized loss availableforsale securities net foreign currency translation adjustment unrealized gain cash flow hedges net comprehensive income issuances employee stock purchase plan stock option exercises net tax benefits employee stock plans compensatory stock transactions balance december net loss unrealized loss availableforsale securities net foreign currency translation adjustment unrealized loss cash flow hedges net comprehensive loss conversion convertible subordinated debt acquisition triangle pharmaceuticals inc issuances employee stock purchase plan stock option exercises net tax benefits employee stock plans amortization deferred stock compensation compensatory stock transactions balance december net income unrealized loss availableforsale securities net foreign currency translation adjustment unrealized loss cash flow hedges net comprehensive income conversion convertible senior debt net debt issuance costs issuances employee stock purchase plan stock option exercises net tax benefits employee stock plans amortization deferred stock compensation compensatory stock transactions balance december see accompanying notes gilead sciences inc consolidated statements cash flows thousands year ended december operating activities net income loss adjustments reconcile net income loss net cash provided operating activities depreciation amortization purchased inprocess research development asset impairment loss disposal property plant equipment loss gain marketable securities deferred tax assets tax benefits employee stock plans noncash transactions changes operating assets liabilities accounts receivable net inventories prepaid expenses assets accounts payable accrued liabilities deferred revenue net cash provided operating activities investing activities purchases marketable securities proceeds sales maturities marketable securities acquisition triangle net assets net cash acquired acquisition real estate capital expenditures issuance note triangle net cash provided used investing activities financing activities proceeds issuances common stock repayments longterm debt proceeds issuance convertible senior notes net issuance costs net cash provided financing activities effect exchange rate changes cash net increase decrease cash cash equivalents cash cash equivalents beginning year cash cash equivalents end year supplemental disclosure cash flow information interest paid income taxes paid noncash investing financing activities common stock issued upon conversion debt reclassification deferred debt issuance costs additional paidin capital upon conversion debt see accompanying notes gilead sciences inc notes consolidated financial statements december organization summary significant accounting policies overview gilead sciences inc gilead incorporated delaware june biopharmaceutical company discovers develops commercializes therapeutics advance care patients suffering lifethreatening diseases multinational company revenues eight approved products marketing operations eleven countries focus research clinical programs antiinfectives currently market viread tenofovir disoproxil fumarate emtriva emtricitabine truvada emtricitabine tenofovir disoproxil fumarate treatment hiv infection hepsera adefovir dipivoxil treatment chronic hepatitis b infection ambisome amphotericin b liposome injection treatment fungal infection vistide cidofovir injection treatment cmv retinitis roche markets tamiflu oseltamivir phosphate treatment influenza royalty paying collaborative agreement us january eyetech started market macugen pegaptanib sodium injection united states treatment neovascular agerelated macular degeneration milestone royalty paying collaborative agreement us accompanying consolidated financial statements include accounts gilead whollyowned subsidiaries significant intercompany transactions eliminated certain prior year amounts reclassified consistent current year presentation see research development expenses stock splits march september gilead completed twoforone stock splits effected form stock dividends stockholders record february august respectively accordingly share per share amounts periods presented reflect stock splits critical accounting policies estimates judgments preparation consolidated financial statements requires us make estimates judgments affect reported amounts assets liabilities revenues expenses related disclosure assets liabilities ongoing basis management evaluates estimates including related revenue recognition allowance doubtful accounts inventories clinical trial accruals tax provision base estimates historical experience various market specific relevant assumptions believed reasonable circumstances results form basis making judgments carrying values assets liabilities readily apparent sources actual results may differ significantly estimates revenue recognition recognize revenue product sales persuasive evidence arrangement exists delivery customer occurred price fixed determinable collectibility reasonably assured provide customers general right product return however accept returns products united states expired one year expiration products gilead sciences inc notes consolidated financial statements continued december organization summary significant accounting policies continued deemed damaged defective received customer upon recognition revenue product sales provisions made estimated future returns products may expire government reimbursements certain distributor fees customer incentives cash discounts prompt payment estimates government reimbursements cash discounts based contractual terms expectations regarding utilization rates programs estimates distributor fees based contractual terms estimates product returns including new products based ongoing analysis industry historical return patterns well third party data assist us monitoring channel inventory levels subsequent prescriptions contract revenue research development recorded performance occurs earnings process completed based performance requirements contract nonrefundable contract fees performance obligations exist continuing involvement gilead recognized earlier payments received collection reasonably assured revenue nonrefundable upfront license fees milestone payments continue involvement development collaboration obligation supply product recognized performance occurs obligations completed accordance specific terms gileads obligations types arrangements revenue recognized manufacturing obligation fulfilled ratably development period revenue associated substantive atrisk milestones recognized based upon achievement milestones defined respective agreements advance payments received excess amounts earned classified deferred revenue royalty revenue sales ambisome recognized month following corresponding sales occur royalty revenue sales hepsera tamiflu vistide recognized received quarter following quarter corresponding sales occur shipping handling costs shipping handling costs incurred inventory purchases product shipments recorded cost goods sold consolidated statements operations research development expensesmajor components research development rd expenses consist personnel costs including salaries benefits clinical studies performed contract research organizations cros materials supplies overhead allocations consisting various administrative facilities related costs rd activities also separated three main categories research clinical development pharmaceutical development research costs typically consist preclinical toxicology work clinical development costs include phase clinical trials pharmaceutical development costs consist product formulation chemical analysis gilead sciences inc notes consolidated financial statements continued december organization summary significant accounting policies continued charge research development costs including clinical preclinical study costs expense incurred consistent statement financial accounting standards sfas accounting research development costs costs significant component rd expenses clinical preclinical studies performed third party cros accrue costs clinical studies performed cros straightline basis service periods specified contracts adjust estimates required based upon ongoing review level effort costs actually incurred cro initially estimate work performed contracts occurs ratably service periods expected milestone event total contract completion date expected completion dates estimated based upon terms contracts past experience similar contracts monitor levels performance contract including extent patient enrollment activities communications cros adjust estimates required quarterly basis expenses reflect actual effort expended cro material cro contracts terminable us upon written notice gilead generally liable actual effort expended cro point time contract regardless payment status amounts paid advance services performed refunded contract terminated contracts include additional termination payments become due payable gilead terminates contract additional termination payments recorded contract terminated order better reflect nature european phase clinical trials gilead began recording costs rd expenses amounts previously classified selling general administrative expenses consolidated statements operations order consistent current period presentation million million expenses reclassified selling general administrative research development expenses years ended december respectively advertising expenses expense costs advertising including promotional expenses incurred advertising expenses million million million stockbased compensation accordance provisions sfas accounting stockbased compensation amended sfas accounting stockbased compensationtransition disclosure sfas elected continue follow accounting principles board opinion apb accounting stock issued employees interpretation fin accounting certain transactions involving stock compensationan interpretation apb opinion accounting employee stock option plans apb exercise price gileads employee director stock options equals exceeds fair value underlying stock date grant compensation expense recognized although elected follow intrinsic value method prescribed apb evaluate approach accounting stock options light recent industry regulatory developments gilead sciences inc notes consolidated financial statements continued december organization summary significant accounting policies continued table presents net income loss basic diluted net income loss per share compensation cost gilead nexstar pharmaceuticals inc nexstar triangle stock option plans employee stock purchase plan espp determined based estimated fair value awards plans grant purchase date accordance sfas thousands except per share amounts year ended december net income lossas reported add stockbased employee compensation expense included reported net income loss net related tax effects deduct total stockbased employee compensation expense determined fair value based method awards net related tax effects pro forma net income loss net income loss per share basicas reported basicpro forma dilutedas reported dilutedpro forma fair values awards granted stock option plans espp estimated grant purchase dates using blackscholes option valuation model blackscholes option valuation model developed use estimating fair value traded options vesting restrictions fully transferable addition option valuation models require input highly subjective assumptions including expected stock price volatility employee stock options characteristics significantly different traded options models may developed future may generate fair values differ calculated based blackscholes calculate estimated fair value awards used multiple option approach following assumptions year ended december expected life years vesting date stock options espp discount rate stock options espp volatility expected dividend yield gilead sciences inc notes consolidated financial statements continued december organization summary significant accounting policies continued fourth quarter refined volatility assumptions used arrive fair value stock awards purposes calculating expected volatility rate began using time period better reflected current stage development length time public company several drug approvals past years enabled us achieve positive cash flow operations believe estimated volatility rates better reflect expected volatility common stock future recent threeyear time period used purposes calculating expected volatility twoyear time period used derive weighted average volatility fourth quarter weighted average volatility first three quarters weighted average estimated fair value espp shares purchased earnings loss per share basic earnings loss per share calculated based weightedaverage number common shares outstanding year diluted earnings loss per share calculated based weightedaverage number common shares dilutive securities dilutive potential common shares resulting assumed exercise outstanding stock options equivalents determined based treasury stock method dilutive potential common shares resulting assumed conversion convertible notes determined based ifconverted method following table reconciliation numerator denominator used calculation basic diluted earnings loss per share thousands year ended december numerator net income loss used calculation basic earnings loss per share interest expense makewhole payment convertible debt redemption net income loss used calculation diluted earnings loss per share denominator weightedaverage common shares outstanding used calculation basic earnings loss per share effect dilutive securities stock options equivalents convertible debt weightedaverage common shares outstanding used calculation diluted earnings loss per share gilead sciences inc notes consolidated financial statements continued december organization summary significant accounting policies continued diluted net loss per share excludes prorated effect million convertible subordinated notes would convert approximately million shares effect million convertible senior notes would convert approximately million shares outstanding stock options equivalents million shares effects antidilutive diluted net income per share excludes effects million convertible subordinated notes would convert approximately million shares million convertible senior notes would convert approximately million shares effects assumed conversions antidilutive cash cash equivalents consider highly liquid investments insignificant interest rate risk remaining maturity three months less purchase date cash equivalents may enter overnight repurchase agreements purchase securities obligation resell following day securities purchased agreements resell recorded face value reported cash cash equivalents investment policy may enter repurchase agreements repos major banks authorized dealers provided repos collateralized us government securities fair value least fair value securities sold gilead eligible instruments investment policy included cash equivalents include commercial paper money market funds bank obligations marketable nonmarketable securities determine appropriate classification marketable securities consist solely debt securities time purchase reevaluate designation balance sheet date marketable securities classified availableforsale carried estimated fair values reported either cash equivalents marketable securities december cash cash equivalents include million securities designated availableforsale million december unrealized gains losses availableforsale securities excluded earnings reported separate component stockholders equity interest income net includes interest dividends amortization purchase premiums discounts realized gains losses sales securities cost securities sold based specific identification method regularly review investments otherthantemporary declines fair value determine decline fair value investment accounting basis otherthantemporary reduce carrying value securities hold record loss amount decline reductions required past three years result entering collaborations time time gilead may hold stock nonpublic companies record nonmarketable securities cost noncurrent assets less amounts otherthantemporary impairment regularly review investments indicators impairment investments nonmarketable securities material periods presented recognized otherthantemporary declines past three years gilead sciences inc notes consolidated financial statements continued december organization summary significant accounting policies continued concentrations risk subject credit risk portfolio cash equivalents marketable securities policy limit amounts invested securities duration industry group investment type issuer except securities issued us government exposed significant concentrations credit risk financial instruments goals investment policy order priority follows safety preservation principal diversification risk liquidity investments sufficient meet cash flow requirements competitive aftertax rate return also subject credit risk accounts receivable related product sales significant amount trade accounts receivable arises product sales viread united states europe certain countries payments typically slow primarily greece italy portugal spain accounts receivable balances significant cases slow payment practices reflect pace governmental entities reimburse customers turn may increase financial risk related certain customers sales customers countries tend relatively slow paying past increased future may increase average length time accounts receivable outstanding december past due accounts receivable greece italy portugal spain totaled approximately million approximately million days past due based contractual terms receivables december past due receivables countries million approximately million days past due date experienced significant losses respect collection accounts receivable believe past due accounts receivable net allowances reflected consolidated balance sheet collectible perform credit evaluations customers financial condition generally required collateral many materials utilize operations made one facility example depend single suppliers high quality amphotericin b distearoylphosphatidylcholine high quality cholesterol used manufacture ambisome well currently one contract manufacturer qualified manufacture truvada tablets supplies suppliers interrupted reason may unable ship viread ambisome hepsera emtriva vistide truvada supply products development clinical trials accounts receivable trade accounts receivable recorded net allowances cash discounts prompt payment doubtful accounts government chargebacks sales returns estimates cash discounts government chargebacks sales returns based contractual terms historical trends expectations regarding utilization rates programs estimates allowance doubtful accounts determined based existing contractual obligations historical payment patterns customers individual customer circumstances analysis days sales outstanding customer geographic region review local economic environment potential impact government funding reimbursement practices historically level uncollectible accounts receivable written insignificant consistent managements expectations gilead sciences inc notes consolidated financial statements continued december organization summary significant accounting policies continuedinventories inventories recorded lower cost market cost determined firstin firstout basis periodically review composition inventory order identify obsolete slowmoving otherwise unsaleable items unsaleable items observed alternate uses inventory record writedown net realizable value period impairment first recognized historically inventory writedowns insignificant consistent managements expectations property plant equipment property plant equipment stated cost less accumulated depreciation amortization depreciation amortization recognized using straight line method land depreciated estimated useful lives follows years description estimated useful life buildings improvements laboratory manufacturing equipment office computer equipment leasehold improvements life related lease office computer equipment includes capitalized computer software capitalized software purchased internally developed computer software leasehold improvements capitalized leased equipment amortized shorter lease term assets useful life amortization capitalized leased equipment included depreciation expense capitalized interest construction progress included property plant equipment interest capitalized insignificant intangible assets intangible assets definite lives amortized estimated useful lives reviewed impairment facts circumstances suggest carrying value assets may recoverable inplace lease intangible asset amortized remaining period related lease term discussed note impairment longlived assets carrying value longlived assets reviewed regular basis existence facts circumstances internally externally may suggest impairment specific potential indicators impairment include significant decrease fair value asset significant change extent manner asset used significant physical change asset gilead sciences inc notes consolidated financial statements continued december organization summary significant accounting policies continued significant adverse change legal factors business climate affects value asset adverse action assessment us food drug administration another regulator accumulation costs significantly excess amount originally expected acquire construct asset operating cash flow losses combined history operating cash flow losses projection forecast demonstrates continuing losses associated incomeproducing asset indication impairment test recoverability comparing estimated undiscounted future cash flows expected result use asset eventual disposition carrying amount asset estimating future cash flows assets liabilities grouped lowest level identifiable cash flows largely independent cash flows generated groups undiscounted future cash flows less carrying amount asset impairment loss measured excess carrying value asset estimated fair value recognized cash flow estimates used calculations based managements best estimates using appropriate customary assumptions projections time foreign currency translation transactions contracts adjustments resulting translating financial statements foreign subsidiaries us dollars excluded determination net income loss accumulated separate component stockholders equity net foreign exchange transaction gains losses reported selling general administrative expenses consolidated statements operations realized losses million million realized gains million hedge certain foreign currency exposures related outstanding trade accounts receivable forecasted product sales foreign exchange forward contracts general market risks contracts offset corresponding gains losses transactions hedged exposure credit risk contracts function changes interest currency exchange rates therefore varies time gilead limits risk counterparties contracts may unable perform transacting major us banks also limit risk loss entering contracts provide net settlement maturity therefore overall risk loss event counterparty default limited amount unrecognized unrealized gains outstanding contracts ie contracts positive fair value date default enter speculative foreign currency transactions write options presently hedge net investment foreign subsidiaries accounting hedges net monetary assets liabilities record changes fair value selling general administrative expense derivative instruments designated hedges sfas nos accounting derivative instruments hedging activities collectively referred sfas gilead sciences inc notes consolidated financial statements continued december organization summary significant accounting policies continued selectively hedge anticipated currency exposures purchasing forward contracts hedge anticipated product sales next year less designated cash flow hedges sfas unrealized gains losses underlying forward contracts recorded comprehensive income recognized earnings forecasted transaction occurs december december net unrealized losses open foreign exchange forward contracts million million respectively losses revenue hedges reduced product sales million million million notional amounts forward exchange contracts outstanding million december million december contracts maturities one year less see note discussion derivative financial instruments fair value financial instruments financial instruments consist principally cash cash equivalents marketable securities accounts receivable certain noncurrent assets forward foreign exchange contracts accounts payable longterm obligations cash cash equivalents marketable securities forward foreign exchange contracts hedge accounts receivable reported respective fair values balance sheet forward foreign exchange contracts hedge firmly committed purchases forecasted sales recorded fair value net related deferred gain loss resulting reported net balance zero gilead called convertible senior notes redemption october converted million shares gilead common stock november december fair value convertible senior notes million carrying value million gilead called convertible subordinated notes redemption november converted million shares gilead common stock december fair value convertible senior notes december determined obtaining quotes market maker notes believe remaining financial instruments reported consolidated balance sheet amounts approximate current fair values recent accounting pronouncement december fasb issued sfas revised sharebased payment sfas r revision sfas sfas r supercedes apb amends sfas statement cash flows sfas r requires sharebased payments employees directors including grants stock options recognized statement operations based fair values beginning first interim annual period june early adoption permitted pro forma disclosures previously permitted sfas longer alternative financial statement recognition expect adopt sfas r third quarter fiscal beginning july sfas r must determine appropriate fair value model used valuing sharebased payments amortization method compensation cost transition method used date adoption transition methods include prospective retroactive adoption options retroactive options prior periods may restated either beginning year adoption periods presented prospective method requires compensation expense recorded unvested stock options restricted stock beginning first quarter gilead sciences inc notes consolidated financial statements continued december organization summary significant accounting policies continued adoption sfas r retroactive methods would record compensation expense unvested stock options restricted stock beginning first period restated currently evaluating requirements sfas r well option valuation methodologies related employee director stock options employee stock purchase plan although yet determined method adoption effect adopting sfas r expect adoption sfas r material impact consolidated results operations earnings per share impact adoption sfas r predicted time depend among things levels sharebased payments granted future method adoption option valuation method used sfas r also requires benefits tax deductions excess recognized compensation cost reported financing cash flow rather operating cash flow required current literature requirement reduce net operating cash flows increase net financing cash flows periods adoption estimate amounts future depend among things employees directors exercise stock options amount operating cash flows recognized prior periods related tax deductions million million million respectively current estimates option values using blackscholes method may indicative results valuation methodologies ultimately adopted gilead derivative financial instruments derivatives recognized either assets liabilities measured fair value enter foreign currency forward contracts hedge changes fair value significant monetary assets liabilities denominated nonfunctional currency derivative designated meets definition fair value hedge changes fair value derivative hedged item recognized earnings enter foreign currency forward contracts generally maturities months less hedge future cash flows related forecasted product sales foreign denominated currencies derivative instruments employed eliminate minimize certain foreign currency exposures confidently identified quantified hedges related forecasted foreign currency product sales designated documented inception respective hedge designated cash flow hedges evaluated effectiveness monthly terms forward contract underlying transaction matched inception forward contract effectiveness calculated comparing fair value contract estimated change fair value underlying hedged item effective component hedge recorded accumulated comprehensive income see note substantially values reported accumulated comprehensive loss december reclassified earnings within months residual changes fair value instruments including resulting cancellation dedesignation hedge contracts ineffectiveness recognized immediately selling general administrative expense impact ineffectiveness significant consolidated statements operations losses million million million hedging contracts recognized consolidated statements ofoperations respectively gilead sciences inc notes consolidated financial statements continued december derivative financial instruments continued result entering collaboration arrangement gilead held warrants purchase stock nonpublic company completed initial public offering january see notes warrants exercised february warrants net exercise feature pursuant sfas classified derivative instruments noncurrent assets december acquisition triangle pharmaceuticals inc january completed acquisition net assets triangle expand antiviral pipeline triangle development stage company particular focus potential therapies hiv including aids hepatitis b virus hbv triangles portfolio consisted several drug candidates clinical trials including emtriva emtricitabine treatment hiv infection emtricitabine treatment chronic hepatitis b amdoxovir treatment hiv infection clevudine treatment chronic hepatitis b july us food drug administration fda granted marketing approval emtriva treatment hiv october european commission granted marketing authorisation emtriva fifteen member states european union triangle acquisition accounted acquisition assets rather business combination accordance criteria outlined emerging issues task force triangle development stage company commenced planned principal operations lacked necessary elements business completed products therefore ability access customers results operations triangle since january included consolidated financial statements primarily consist research development expenses lesser extent selling general administrative expenses december part arrangements contemplated proposed acquisition triangle gilead million loan extended triangle working capital corporate purposes triangle issued gilead unsecured convertible promissory note upon completion acquisition january loan eliminated consolidated financial statements aggregate purchase price million including cash paid million outstanding stock fair value stock options assumed million direct transaction costs million employee related costs million part purchase established workforce reduction plan also assumed obligations various change control agreements acquisition date approximately million employee termination costs change control obligations recorded liability paid period approximately two years december approximately remained liability gilead sciences inc notes consolidated financial statements continued december acquisition triangle pharmaceuticals inc continued following table summarizes purchase price allocation january thousands net tangible assets assembled workforce deferred compensation inprocess research development million net tangible assets includes assumed liabilities million million value assigned assembled workforce amortized three years estimated useful life asset deferred compensation represents intrinsic value unvested stock options assumed transaction amortized remaining vesting period options extends january upon reversal deferred tax asset valuation allowance fourth quarter remaining million assembled workforce asset eliminated see note gilead sciences inc notes consolidated financial statements continued december acquisition triangle pharmaceuticals inc continued approximately million purchase price allocated purchased inprocess research development represented fair value triangles incomplete research development programs yet reached technological feasibility alternative future use acquisition date summary programs acquisition date updated subsequent developments follows estimated acquisition date fair value program description status development millions emtricitab ine f nucleoside analogue four phase studies completed prior hiv shown acquisition date us marketing approval inhibitor hiv replication received fda july patients emtriva european union approval received european commission october emtricitabine fixeddose coformulation acquisition date work tenofovir df tenofovir emtricitabine commenced potential coformulation fixed dose except extent work combination emtricitabine single agent hiv progressing march applications therapy marketing approval submitted united states european union august marketing approval united states received fda truvada fixeddose coformulation tenofovir emtricitabine marketing approval european union received february amdoxovir purine dioxolane program phase trials hiv nucleoside may offer acquisition date terminated advantages licensing agreement emory university marketed nucleosides university georgia research activity foundation inc development drug resistant discontinued viruses exhibited patients hiv infection clevudine pyrimidine nucleoside program phase trials hbv analogue acquisition date august licensing shown inhibitor agreement bukwang pharm ind co hbv replication patients ltd terminated development chronically infected hbv discontinued emtricitabine inhibitor hbv one phase trial completed hbv replication patients december chronically infected hbv gilead sciences inc notes consolidated financial statements continued december acquisition triangle pharmaceuticals inc continued value acquired inprocess research development determined estimating related future net cash flows using present value risk adjusted discount rate discount rate significant assumption based estimated weighted average cost capital adjusted upward risks associated projects acquired projected cash flows acquired projects based estimates revenues operating profits related projects considering stage development potential product acquired time resources needed complete development approval product life potential commercialized product associated risks including inherent difficulties uncertainties developing drug compound including obtaining fda regulatory approvals risks related viability potential alternative treatments future target markets acquisition real estate september completed purchase foster city california campus approximately million cash purchase included buildings totaling square feet office laboratory space accordance sfas business combinations sfas goodwill intangible assets purchase price allocated land buildings existing inplace leases based estimated relative fair values land buildings recorded million million respectively fair value buildings depreciated remaining economic life estimated years used market approach value existing leases acquired recorded intangible asset approximately million amortized straightline basis net rental income approximately two years remaining term leases accumulated amortization intangible asset million million december december respectively net rental income generate leases amortization intangible asset included interest income net approximately million year ended december million year ended december future net rental income received existing leases million million prior amortization inplace lease asset asset impairment fourth quarter recorded asset impairment charge million certain longlived assets primarily leasehold improvements manufacturing laboratory equipment classified held use noncash charge driven decision terminate liposomal research development activities san dimas discontinue daunoxome daunorubicin citrate liposome injection product line impairment based analysis undiscounted cash flows generated affected assets compared carrying value carrying value exceeded related estimated undiscounted cash flows wrote carrying value longlived assets estimated fair value accordance sfas accounting impairment disposal longlived assets sfas estimated fair value derived using expected cash flow approach gilead sciences inc notes consolidated financial statements continued december asset impairment continued subsequent decision discontinue daunoxome product line received unanticipated requests europe asking gilead reconsider selling daunoxome result requests management decided continue selling product certain countries still evaluating supply sales strategy respect daunoxome accordance sfas write assets continue used daunoxome product line established new cost basis assets adjusted new facts circumstances gain loss marketable securities eyetech pharmaceuticals march entered agreement eyetech pharmaceuticals inc eyetech relating proprietary aptamer eye currently known macugen pegaptanib sodium injection pursuant agreement received warrant purchase shares eyetech series b convertible preferred stock exercisable price per share january eyetech completed initial public offering common stock time adjusted carrying value warrant estimated fair value resulting gain million included consolidated statement operations year ended december gain loss marketable securities fair value warrant estimated using blackscholes valuation model volatility rate discount rate end first quarter exercised warrant net basis using shares eyetech common stock consideration exercise price subsequently held shares eyetech common stock second quarter sold eyetech shares held realized gain approximately million included interest income net consolidated statement operations year ended december osi pharmaceuticals july gilead sold remaining shares osi common stock approximately million shares partial consideration sale oncology assets osi december time recorded fair market value approximately million connection sale remaining shares recognized nonoperating loss approximately million reflected consolidated statement operations year ended december gain loss marketable securities gilead sciences inc notes consolidated financial statements continued december availableforsale securities following summary availableforsale securities recorded cash equivalents marketable securities consolidated balance sheets estimated fair values availableforsale securities based prices obtained commercial pricing services thousands gross gross amortized unrealized unrealized estimated cost gains losses fair value december us treasury securities obligations us government agencies corporate debt securities assetbacked securities debt securities total december us treasury securities obligations us government agencies corporate debt securities assetbacked securities debt securities total debt securities consist primarily money market funds december december securities net unrealized gain loss ofapproximately million million respectively following table presents certain information related sales availableforsale securities thousands year ended december proceeds sales gross realized gains sales gross realized losses sales december million portfolio marketable securities excludes million assetbacked securities contractual maturity less one year million portfolio contractual maturity greater one year less three years none estimated maturities assetbacked securities exceed three years december marketable securities continuous unrealized loss position one year gilead sciences inc notes consolidated financial statements continued december balance sheet detail thousands december inventories raw materials work process finished goods total property plant equipment net buildings improvements including leasehold improvements laboratory manufacturing equipment office computer equipment capitalized leased equipment construction inprogress less accumulated depreciation amortization subtotal land total accrued compensation employee benefits accrued bonuses accrued compensation employee benefits total accrued liabilities accrued medicaid rebates fair value forward foreign currency contracts value added taxes payable income taxes payable accrued royalty expenses liabilities total joint venture bristolmyers squibb december entered collaboration bristolmyers squibb company bms develop commercialize fixeddose combination gileads truvada bmss sustiva efavirenz united states structured joint venture gilead bms formed limited liability company bristol myers squibb gilead sciences llc terms collaboration gilead bms granted royaltyfree sublicenses joint venture use respective companyowned technologies return granted license joint venture use intellectual property results collaboration ownership interests joint venture gilead bms gilead sciences inc notes consolidated financial statements continued december joint venture bristolmyers squibb continuedreflect respective economic interests based fraction estimated net selling price fixeddose combination product attributable truvada sustiva respectively adjusted annual basis since net selling price truvada may change time relative net selling price sustiva gileads bmss respective economic interests joint venture may vary annually gilead primary responsibility clinical development activities regulatory filings relating new products resulting collaboration bms gilead share marketing sales efforts parties provide equivalent sales force efforts minimum number years daily operations joint venture governed four primary joint committees gilead responsible accounting financial reporting product distribution joint venture parties agreed provide respective bulk active pharmaceutical ingredients joint venture approximate market values joint ventures total equity investment risk expected sufficient allow finance operational activities without ongoing funding gilead bms joint venture attributes believe result representing variable interest entity set forth fasb interpretation consolidation variable interest entities fin r expect consolidate results operations financial position joint venture concluded primary beneficiary party absorb majority joint ventures expected losses although primary beneficiary legal structure joint venture limits recourse creditors general credit assets gilead financial information consolidate operations joint venture yet begun december capital contributions made gilead bms beginning expect consolidate joint venture record minority interest owned bms significant intercompany transactions eliminated collaborative arrangements contracts achillion pharmaceuticals november entered exclusive license collaboration agreement achillion pharmaceuticals inc achillion agreement granted worldwide rights research development commercialization certain small molecule hcv replication inhibitors involving hcv protease treatment infection hepatitis c virus hcv collaboration achillion obligated continue development compounds according mutually agreed upon development plan completion proofofconcept clinical study hcvinfected patients costs incurred achieve proofof concept shared equally gilead achillion following proofofconcept study gilead obligated assume full responsibilities incur costs associated development commercialization compounds warranting development achillion option participate us commercialization efforts future products arising collaboration conjunction signing collaboration gilead paid million upfront license fee recorded research development expense gilead sciences inc notes consolidated financial statements continued december collaborative arrangements contracts continued future alternative use licensed technology also made million investment purchased million shares achillions convertible preferred stock recorded noncurrent assets additionally also agreed make payments achillion upon achievement certain milestones outlined agreement pay royalties future net sales products arising collaboration genelabs technologies september entered license research collaboration agreement genelabs technologies inc genelabs research develop commercialize certain genelabs novel nucleoside inhibitors hcv polymerase treatment chronic infection caused hcv conjunction signing collaboration agreement paid million upfront license fee recorded research development expense future alternative use technology initially agreed upon term three years genelabs obligated lead research efforts gilead option extend research term collaboration additional year gilead lead development commercialization activities agreed provide annual funding full time equivalents fte expect record research development expense obligated make additional payments upon achievement certain milestones pay royalties future net sales selected compounds developed approved relation collaboration chiron corporation august entered nonexclusive licensing agreement chiron corporation chiron research development commercialization small molecule therapeutics selected hcv drug targets agreement gilead received nonexclusive rights use chirons hcv technology develop commercialize products treatment hcv terms agreement paid chiron upfront license fee million recorded research development expense future alternative use licensed technology also agreed make additional payments chiron certain clinical regulatory contractually determined milestones met made million payments chiron recorded research development expense additionally obligated make royalty payments event product developed using licensed technology japan tobacco inc july gilead entered licensing agreement japan tobacco inc japan tobacco japan tobacco commercialize products hiv product portfolio japan agreement includes viread emtriva truvada terms agreement received upfront license fee million entitled receive additional cash payments upon achievement certain milestones japan tobacco also pay us royalty net sales products japan upfront fee recorded deferred revenue amortized contract revenue period supply products japan tobacco approximately years december received million milestone payments japan tobacco related japanese regulatory approval marketing authorization viread amortizing gilead sciences inc notes consolidated financial statements continueddecember collaborative arrangements contracts continued remaining period upfront license fee january japan tobacco submitted marketing authorization applications emtriva truvada japanese regulatory authorities emory university april triangle obtained january acquired part acquisition triangle exclusive worldwide license emory universitys emory rights purified forms emtricitabine use hiv hepatitis b fields obligated make certain milestone royalty payments emory including annual minimum royalties beginning third year first fda registration granted antihiv product incorporating emtricitabine technology united states third year first registration granted antihepatitis b product incorporating emtricitabine technology certain major market countries triangle began paying license maintenance fees development milestones yet achieved due launch emtriva began paying royalties emory respect emtricitabine hiv indication paid royalties million million respectively net sales emtriva net sales truvada also incorporates emtricitabine technology launched license agreement emory terminates upon later patent expiration expiration obligation pay royalties addition right terminate agreement entirety respect one indications hiv hbv one countries prior expiration time upon days notice glaxosmithkline april gilead gsk entered licensing agreement providing gsk rights commercialize hepsera oral antiviral treatment chronic hepatitis b asia latin america certain territories agreement retained rights hepsera united states canada eastern western europe australia new zealand turkey gsk received exclusive rights develop hepsera solely treatment chronic hepatitis b territories significant include china japan korea taiwan addition gsk paid us upfront licensing fee million could pay us million upon achievement gsk certain regulatory development commercial milestones million million received us approval hepsera million received canadian approval hepsera aggregate million received commercial approvals hepsera japan south korea taiwan gsk full responsibility development commercialization hepsera territories upfront license fee approval milestones recorded deferred revenue total million million million recognized contract revenue respectively million balance deferred revenue december amortized contract revenue period supply hepsera gsk agreement approximately years addition gsk required pay gilead royalties net product sales gsk generates sales hepsera epivirhbvzeffix gsks hepatitis product gsk territories gilead began receiving royalties gsks sales hepsera first quarter recorded million royalty revenue recognize royalty revenue gsk quarter following quarter related hepsera sales occur gilead sciences inc notes consolidated financial statements continued december collaborative arrangements contracts continued osi pharmaceuticals december completed sale oncology assets osi pharmaceuticals osi terms agreement entitled additional payments osi million either cash combination cash osi stock osi reaches certain development milestones nx advanced oncology product candidates sold osi related manufacturing agreement produce nx gs l two liposomal products included sale manufacturing facility san dimas california recognized million million million respectively contract revenue manufacturing agreement archemix october entered agreement archemix corporation relating selex technology agreement gave archemix exclusive rights selex process including therapeutic commercial applications extent already licensed preexisting agreements archemix paid us million million required license agreement license equity holdings inc ulehi paid receipts ulehi therefore recognizing million million contract revenue respectively also received warrant purchase shares archemix common stock value material required license agreement ulehi transferred warrant upon receipt since transferred remainder warrant ulehi additional payments due archemix agreement eyetech march entered agreement eyetech pharmaceuticals inc relating macugen macugen inhibitor vascular endothelial growth factor vegf known play role development certain ophthalmic diseases terms agreement eyetech received worldwide rights therapeutic uses macugen responsible research development costs received million upfront license fee eyetech april recognized revenue ratably oneyear period provided clinical supplies product eyetech also entitled additional cash payments eyetech million eyetech reaches certain macugen milestones well royalties worldwide net sales macugen december entered agreement eyetech supply macugen eyetech three years recorded contract revenue million million respectively connection clinical supplies provided eyetech milestones achieved eyetech recognized contact revenue million milestone payments eyetech second third quarters upon filing new drug applications europe us macugen january eyetech received fda approval sale macugen united states agreement eyetech expires upon later ten years first commercial sale product developed date last patent expires agreement gilead sciences inc notes consolidated financial statements continued december collaborative arrangements contracts continued additionally received warrant purchase shares eyetech series b convertible preferred stock exercisable price per share price stock issued investors see note discussion warrant fujisawa rights market ambisome subject agreement gilead fujisawa healthcare inc successor fujisawa usa inc fujisawa terms fujisawa agreement amended fujisawa gilead copromote ambisome united states fujisawa sole marketing rights ambisome canada exclusive marketing rights ambisome rest world provided pay royalties fujisawa connection sales significant asian markets including china india japan korea taiwan connection us sales fujisawa purchases ambisome gilead manufacturing cost sales canada fujisawa purchases ambisome manufacturing cost plus specified percentage fujisawa collects payments sale ambisome united states canada receive fujisawas gross profits sale ambisome united states gross profits include deduction cost goods sold giving us current effective royalty rate approximately fujisawas net sales ambisome united states connection agreement recorded royalty revenue million million million sumitomo september gilead sumitomo entered agreement pursuant sumitomo agreed develop market ambisome japan terms agreement sumitomo paid us initial million licensing fee less withholding taxes million october million milestone payment less withholding taxes million march sumitomo also required make additional payments us certain clinical commercial milestones met pay us royalties japanese ambisome sales agreement gilead obligated provide certain quantity ambisome sumitomo charge recognizing payments received revenue supply period ambisome yet approved marketing japan roche september gilead entered collaboration agreement hoffmannla roche roche develop commercialize therapies treat prevent viral influenza agreement roche received exclusive worldwide rights gileads proprietary influenza neuraminidase inhibitors recognized contract revenue million milestone payments european approval tamiflu treatment prophylaxis recognized contract revenue million milestone payments japanese approval tamiflu prophylaxis last milestones receivable agreement addition roche required pay gilead royalties net product sales tamiflu subject reduction certain defined manufacturing costs recorded total million million million tamiflu royalties respectively recognize royalty revenue roche quarter following quarter related tamiflu sales occur gilead sciences inc notes consolidated financial statements continued december collaborative arrangements contracts continued iocbrega gilead entered agreements institute organic chemistry biochemistry academy sciences czech republic rega stichting iocbrega relating certain nucleotide compounds discovered two institutions agreements gilead received exclusive right manufacture use sell nucleotide compounds gilead obligated pay iocbrega percentage net revenues received sales products containing compounds subject minimum royalty payments products covered agreement include vistide hepsera viread exclude tamiflu august agreements iocbrega amended include truvada future fixeddose combination products contain licensed technology gilead currently makes quarterly payments iocbrega based percentage vistide hepsera viread truvada net sales paid royalties million million million iocbrega respectively december agreements iocbrega amended provide reduced royalty rate future sales hepsera viread return front payment gilead million upon signing agreement payment recorded longterm prepaid royalty classified noncurrent assets balance sheet december prepaid royalty recognized royalty expense expected commercial life viread hepsera amortization million payment began product launch dates viread hepsera longterm obligations longterm obligations consist following thousands december capital lease obligations monthly installments interest rates ranging total longterm obligations less current portion longterm obligations due one year future minimum lease payments capital lease obligations follows thousands year ending december less amount representing interest total gilead sciences inc notes consolidated financial statements continued december longterm obligations continued terms various agreements require us comply certain financial operating covenants december compliance covenants convertible notes december gilead issued million convertible senior notes due december notes convertible total shares gilead common stock per share convertible senior notes provisionally redeemable whole part option gilead time june specified redemption prices plus accrued interest debt issuance costs million incurred connection issuance notes recorded noncurrent assets amortized interest expense straightline basis contractual term notes gilead called convertible senior notes redemption october issued shares gilead common stock note holders upon conversion november redemption price equal principal amount notes redeemed plus accrued unpaid interest redemption date connection redemption gilead paid makewhole payment million note holders representing equivalent per principal value notes less interest actually paid accrued unpaid date issuance notes redemption date upon conversion million unamortized balance related debt issuance costs reclassified additional paidin capital december gilead issued million convertible subordinated notes due december convertible subordinated notes convertible total shares gilead common stock per share convertible subordinated notes redeemable whole part option gilead time december specified redemption prices plus accrued interest debt issuance costs million incurred connection issuance convertible subordinated notes recorded noncurrent assets amortized interest expense straightline basis contractual term convertible subordinated notes november gilead called convertible subordinated notes redemption converted notes shares common stock december upon conversion million unamortized balance related debt issuance costs reclassified additional paidin capital commitments contingencies lease arrangements entered various longterm noncancelable operating leases equipment facilities facility leases foster city california san dimas california durham north carolina expire various dates foster city lease two fiveyear renewal options addition gilead option purchase foster city properties specified amount durham lease two seven year renewal options also operating leases sales marketing administrative facilities europe australia various terms equipment leases include corporate airplane initial term two years annual renewal option ten years gilead sciences inc notes consolidated financial statements continued december commitments contingencies continued lease expense operating leases totaled approximately million million million aggregate noncancelable future minimum rental payments operating leases follows thousands years ending december operating leases thereafter legal proceedings complaints following cases allege large number defendants including gilead overcharged governmental entity named plaintiff pharmaceutical products furnished participants medicaid program general complaints assert claims federal state law except forthe alabama state action includes state law claims seek treble damage attorneys fees litigations preliminary stage possible predict outcome indeed date gilead served process cases except county westchester v abbott laboratories et al intend defend cases vigorously outcome cases predicted time amounts accrued county westchester v abbott laboratories et al pending part multidistrict litigation united states district court district massachusetts lawsuit filed gilead approximately defendants august amended include approximately defendants january city new york v abbott laboratories et al pending part multidistrict litigation united states district court district massachusetts lawsuit filed gilead approximately defendants august amended approximately defendants january county rockland v abbott laboratories et al pending part multidistrict litigation united states district court district massachusetts lawsuit originally name gilead defendant amended include claims gilead well approximately defendants january state alabama v abbott laboratories et al pending circuit court montgomery county alabama lawsuit filed gilead approximately defendants january gilead sciences inc notes consolidated financial statements continued december commitments contingencies continued purported class action complaint filed november united states district court northern district california gilead certain executive officers complaint alleges defendants violated federal securities laws specifically sections b securities exchange act rule b securities exchange commission making certain alleged false misleading statements plaintiff seeks unspecified damages behalf purported class purchasers gileads securities period july october similar actions subsequently filed court issued order consolidating lawsuits single action december february court issued order appointing lead plaintiffs consolidated action april lead plaintiffs behalf purported class filed consolidated amended complaint june gilead individual defendants filed motion dismiss consolidated amended complaint january court granted defendants motion dismiss leave amend amounts accrued date december two purported shareholder derivative lawsuits filed individual shareholders behalf gilead directors certain executive officers superior court state california county san mateo alleging among things defendants violated california corporations code breached fiduciary duties owing gilead gilead named nominal defendant plaintiffs seek unspecified damages behalf gilead connection alleged insider trading period july october defendants alleged breach fiduciary duties abuse control waste mismanagement two cases consolidated single action january third similar case filed february later consolidated prior two cases plaintiffs filed consolidated complaint amended two times recently november gilead demurred consolidated complaint court granted demurrer december plaintiffs filed motion leave file third consolidated amended complaint january court granted plaintiffs motion rendering complaint operative complaint intend demur complaint trial scheduled june outcome cases predicted time amounts accrued also party various legal actions arose ordinary course business believe legal actions material adverse impact business results operations financial position commitments contingencies normal course business may subject contingencies may arise matters product liability claims legal proceedings shareholder suits tax matters accrue contingencies accordance sfas accounting contingencies normal course business entered various firm minimum purchase commitments inventoryrelated materials certain active pharmaceutical ingredient suppliers december approximately million purchase commitments follows million million million million gilead sciences inc notes consolidated financial statements continued december stockholders equity preferred stock gilead shares authorized preferred stock issuable series board directors board authorized determine designation powers preferences rights series reserved shares preferred stock potential issuance preferred share purchase rights plan preferred stock outstanding december employee stock purchase plan gileads employee stock purchase plan espp employees purchase shares gilead common stock based percentage compensationthe purchase price per share must equal least lower market value date offered date purchased total million shares common stock reserved issuance espp december million shares total shares reserved issued espp million shares december stock option plans may gileads stockholders approved gilead adopted equity incentive plan plan replacement stock option plan plan nonemployee directors stock option plan directors plan adoption plan included increase number shares available issuance remaining shares available issuance plan directors plan plan provides issuance various types equity awards incentive stock options nonstatutory stock options stock appreciation rights sar dividend equivalent rights restricted stock performance units performance shares phantom shares plan exercise purchase price incentive stock options shall less fair value gileads common stock date grant case nonstatutory stock options sars per share exercise price shall less fair value gileads common stock date grant case types awards exercise purchase price determined plan administrator incentive stock options typically vest five years pursuant formula determined board expire ten years term awards shall term stated award agreement ten years date grant eligible participants include employees directors consultants gilead except employees eligible incentive stock options compensation committee delegate determines awards granted well vesting terms december shares remaining available future grant plan november gilead adopted plan issuance common stock employees consultants options issued plan discretion board either incentive stock options nonqualified stock options may plan amended exercise price stock options must least equal fair value gileads common stock date grant options vest five years pursuant formula determined board expire ten years plan amended restated april extend term plan may stockholders approved amendment plan increased gilead sciences inc notes consolidated financial statements continued december stockholders equity continued total number authorized shares plan may remaining shares available future grant plan transferred plan additionally options granted plan expire otherwise terminate without exercised shares common stock reserved options become available future grant plan november gilead adopted directors plan issuance common stock nonemployee directors pursuant predetermined formula exercise price options granted directors plan must least equal fair value gileads common stock date grant options granted january vesting five years date grant quarterly five percent installments initial options granted january new directors vest three years date grant equal annual installments annual grants thereafter existing directors vest one year options expire ten years may stockholders approved amendment directors plan increased total number authorized shares plan may remaining shares available grant plan transferred plan additionally options granted plan expire otherwise terminate without exercised shares common stock reserved options become available future grant plan stock plans assumed gilead merger nexstar include stock option plan incentive stock plan director option plan collectively nexstar plans options pursuant nexstar plans issued outstanding july converted options purchase gilead common stock result merger remain subject original terms conditions shares available grant future options nexstar plans stock plans assumed gilead acquisition net assets triangle include stock option plan separate plan former chief executive officer triangle collectively triangle plans options pursuant plan issued outstanding january converted options purchase approximately million shares gilead common stock result acquisition remain subject original terms conditions shares available grant future options either triangle plans gilead sciences inc notes consolidated financial statements continued december stockholders equity continued following table summarizes activity gilead nexstar triangle stock option plans option grants presented table exercise prices less fair value underlying stock grant date shares thousands year ended december weighted weighted weighted average average average exercise exercise exercise shares price shares price shares price outstanding beginning year granted assumed forfeited exercised outstanding end year exercisable end year weighted average fair value options granted following summary gilead options outstanding options exercisable december options thousands options outstanding options exercisable weighted average weighted remaining average weighted options contractual exercise options average exercise range exercise prices outstanding life years price exercisable price total preferred share purchase rights plan november adopted preferred share purchase rights plan rights plan rights plan provides distribution preferred stock purchase right dividend share gilead common stock purchase rights currently exercisable certain conditions involving acquisition proposed acquisition person group common stock purchase rights permit holders holder purchase gilead common stock discount market price time upon payment specified exercise price per purchase right addition event certain business combinations purchase rights permit purchase common stock acquirer discount market price time certain conditions purchase rights may redeemed board whole part price gilead sciences inc notes consolidated financial statements continued december stockholders equity continued per purchase right purchase rights voting privileges attached automatically trade gilead common stock october october board directors approved amendments rights plan first amendment provided among things increase exercise price right plan extension term plan november october second amendment provides among things increase exercise price right plan extension term rights plan october comprehensive income loss comprehensive income loss comprised net income certain changes stockholders equity excluded net income excluded items comprehensive income loss includes changes fair value untriggered effective cash flow hedges changes unrealized gains losses availableforsale securities changes cumulative foreign currency translation account comprehensive income loss years ended december included consolidated statement stockholders equity components comprehensive income loss shown net related taxes underlying assets liabilities held jurisdictions expected generate future tax benefit liability following reclassifications recorded connection net realized gains losses sales securities cash flow hedges previously included comprehensive income loss thousands year ended december net unrealized loss arising year availableforsale securities net tax benefit respectively net unrealized gain loss arising year cash flow hedges reclassification adjustments net tax benefit provision respectively comprehensive loss balance accumulated comprehensive income loss net taxes reported balance sheet consists following components thousands december net unrealized loss availableforsale securities net unrealized loss cash flow hedges net foreign currency translation gain accumulated comprehensive income loss gilead sciences inc notes consolidated financial statements continued december disclosures segments enterprise related information gilead operates one business segment primarily focuses development commercialization human therapeutics infectious diseases products included one segment major products viread tenofovir disoproxil fumarate emtriva emtricitabine truvada emtricitabine tenofovir disoproxil fumarate collectively hiv products ambisome amphotericin b liposome injection accounted product sales years ended december respectively similar economic characteristics including nature products production processes type customers distribution methods regulatory environment product sales consist following thousands year ended december hiv products viread emtriva truvada total hiv products ambisome hepsera vistide daunoxome total product revenues following table summarizes revenues external customers collaborative partners geographic region revenues attributed countries based location customer collaborative partner thousands year ended december united states france spain united kingdom italy germany switzerland european countries countries total revenues gilead sciences inc notes consolidated financial statements continued december disclosures segments enterprise related information continued december net book value property plant equipment million approximately assets located united states december net book value property plant equipment million approximately assets located united states following table summarizes revenues three largest customers distribute drugs primarily united states total revenues year ended december cardinal health inc amerisourcebergen corp mckesson corp income taxes provision benefit income taxes consisted following thousands year ended december federal current deferred state current deferred foreign current deferred foreign pretax income loss million million million gileads foreign subsidiaries generated operating losses reflecting costs building commercial infrastructure europe foreign subsidiaries investment research development efforts unremitted foreign earnings considered permanently invested outside united states us taxes provided approximately million december residual us tax liability amounts remitted would approximately million gilead sciences inc notes consolidated financial statements continued december income taxes continued difference provision benefit taxes income amount computed applying federal statutory income tax rate income loss provision benefit income taxes explained thousands year ended december income loss provision benefit income taxes tax federal statutory rate state taxes net federal benefit benefitted losses change valuation allowance foreign earnings different rates research experimentation credits inprocess research development charge foreign losses different rates provision benefit income taxes tax benefits associated stock option exercises employee stock purchase plan resulted tax benefit million year ended december benefit credited additional paidin capital realized gilead sciences inc notes consolidated financial statements continued december income taxes continued deferred income taxes reflect net tax effects temporary differences carrying amounts assets liabilities financial reporting purposes amounts used income tax purposes significant components deferred tax assets liabilities december follows thousands december deferred tax assets net operating loss carryforwards research tax credit carryforwards reserves accruals currently deductible depreciation related capitalized research development expenses net valuation allowance total deferred tax assets deferred tax liabilities unremitted foreign earnings total deferred tax liabilities net deferred tax assets valuation allowance decreased million million years ended december respectivelywe valuation allowance million million december respectively concluded based standard set forth sfas accounting income taxes likely realize benefits related deferred tax assets assess need valuation allowance quarter end based available evidence approximately million valuation allowance december relates tax benefits stock option deductions credited additional paidin capital realized december us federal net operating loss carryforwards approximately million federal net operating loss carryforwards expire various dates utilized addition federal state tax credit carryforwards approximately million million respectively expire various dates utilized utilization net operating losses tax credit carryforwards may subject annual limitation due ownership change limitations provided internal revenue code similar state provisions annual limitation may result expiration net operating losses credits utilization october american jobs creation act ajca signed law ajca includes deduction certain foreign earnings repatriated defined ajca may elect apply provision qualifying earnings repatriations fiscal started gilead sciences inc notes consolidated financial statements continued december income taxes continued evaluation effects repatriation provision however expect able complete evaluation congress treasury department provide additional clarifying language key elements ajca expect complete evaluation potential effects repatriation provision within reasonable period time following publication additional clarifying language range possible amounts considering repatriation ajca zero million maximum allowable company defined ajca related potential range income tax reasonably estimated december deferred compensation plans gilead maintains one retirement savings plan eligible employees may defer compensation income tax purposes section k internal revenue code gilead plan gilead plan employees may contribute eligible annual compensation gilead makes matching contributions gilead plan contribute employees first contributions annual maximum match total matching contribution expense gilead plan million million million gilead maintains deferred compensation plan directors officers may defer compensation income tax purposes internal revenue code plan officers may contribute annual salaries annual management bonus directors may contribute annual retainer fee amounts deferred participants deposited rabbi trust recorded noncurrent assets consolidated balance sheet beginning directors may also elect receive portion annual cash retainer phantom shares december issued phantom shares participants elect one several distribution dates available plan receive deferred compensation payment gilead sciences inc notes consolidated financial statements continued december quarterly results operations unaudited following table thousands except per share amounts st quarter nd quarter rd quarter th quarter total revenues gross profit product sales total costs expenses net income net income per sharebasic net income per sharediluted st quarter nd quarter rd quarter th quarter total revenues gross profit product sales total costs expenses net income loss net income loss per sharebasic net income loss per sharediluted first quarter gilead recorded pretax gain million related warrants eyetech completed initial public offering fourth quarter gilead recorded expense million connection makewhole payment convertible senior debt holders relation redemption conversion convertible senior debt first quarter gilead completed acquisition net assets triangle recorded charge million purchased inprocess research development third quarter gilead reimbursed million research development expenses resulting settlement contractual dispute vendor fourth quarter gilead recorded noncash impairment charges certain longlived assets million addition recorded income tax benefit million related reduction valuation allowance certain net deferred tax assets september gilead implemented twoforone stock split form stock dividends share per share amounts periods presented restated reflect stock split gilead sciences inc schedule ii valuation qualifying accounts balance additions balance beginning charged charged end period expense deductions period year ended december accounts receivable allowances inventory reserve valuation allowance deferred tax assets year ended december accounts receivable allowances inventory reserve valuation allowance deferred tax assets year ended december accounts receivable allowances inventory reserve valuation allowance deferred tax assets allowances doubtful accounts sales returns cash discounts chargebacks